var title_f29_59_30640="Longitudinal erythronychia melanoma in situ";
var content_f29_59_30640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal erythronychia secondary to melanoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30640=[""].join("\n");
var outline_f29_59_30640=null;
var title_f29_59_30641="Toxicodendron radicans range US";
var content_f29_59_30641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    US range of toxicodendron radicans subspecies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30641=[""].join("\n");
var outline_f29_59_30641=null;
var title_f29_59_30642="Lidocaine (ophthalmic): Pediatric drug information";
var content_f29_59_30642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/30/4579?source=see_link\">",
"    see \"Lidocaine (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/39/12915?source=see_link\">",
"    see \"Lidocaine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8768586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Akten&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10529526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10529547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/30/4579?source=see_link\">",
"      see \"Lidocaine (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anesthesia, ocular: Ophthalmic gel (Akten&reg;): Children and Adults: Apply 2 drops to ocular surface in area where procedure to occur; may reapply to maintain effect",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8768880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, ophthalmic, as hydrochloride [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Akten&reg;: 3.5% (1 mL, 5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8768591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10529544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light. Discard after use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10529527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetic for ophthalmic procedures (FDA approved in adults; refer to product specific information regarding FDA approval in pediatric patients)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8768671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctival hyperemia, corneal epithelial changes, diplopia, visual changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10529528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lidocaine, amide-type local anesthetics, or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10529529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only; not for injection; prolonged use may cause permanent corneal ulceration and/or opacification with loss of vision.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8768698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8768651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8768652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies with systemic lidocaine have not shown teratogenic effects. Lidocaine and the MEGX metabolite cross the placenta. Cumulative exposure from all routes of administration should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10529545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10529546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetic effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 20 seconds to 5 minutes (median: 40 seconds)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 5-30 minutes (mean: 15 minutes)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Busbee BG, Alam A, and Reichel E, \"Lidocaine Hydrochloride Gel for Ocular Anesthesia: Results of a Prospective, Randomized Study,\"",
"      <i>",
"       Ophthalmic Surg Lasers Imaging",
"      </i>",
"      , 2008, 39(5):386-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30642/abstract-text/18831420/pubmed\" id=\"18831420\" target=\"_blank\">",
"        18831420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16014 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30642=[""].join("\n");
var outline_f29_59_30642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768586\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529526\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529547\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768880\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768591\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529544\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529527\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768671\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529528\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529529\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299602\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768698\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768651\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768652\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529545\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10529546\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16014\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16014|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/30/4579?source=related_link\">",
"      Lidocaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/39/12915?source=related_link\">",
"      Lidocaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/54/14184?source=related_link\">",
"      Lidocaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/58/36772?source=related_link\">",
"      Lidocaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/11/20663?source=related_link\">",
"      Lidocaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/3/20535?source=related_link\">",
"      Lidocaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/46/29413?source=related_link\">",
"      Lidocaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33574?source=related_link\">",
"      Lidocaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_59_30643="An adolescents drawing and description of RLS";
var content_f29_59_30643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A drawing and description of restless legs syndrome by a 17-year-old adolescent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The adolescent described the symptoms as follows: \"My restless legs pain feels like the bones deep in my legs are being hit with a hammer. They only feel better if I move them constantly. It keeps me awake at night.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel L Picchietti, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30643=[""].join("\n");
var outline_f29_59_30643=null;
var title_f29_59_30644="Raltegravir: Patient drug information";
var content_f29_59_30644=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Raltegravir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     see \"Raltegravir: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5374882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isentress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5937103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Isentress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to raltegravir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Raised liver enzymes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11998 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30644=[""].join("\n");
var outline_f29_59_30644=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374882\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5937103\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016034\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016033\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016038\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016039\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016041\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016036\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016037\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016042\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016043\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=related_link\">",
"      Raltegravir: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_59_30645="Ketoprofen: Patient drug information";
var content_f29_59_30645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketoprofen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     see \"Ketoprofen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Keto SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Keto-E&reg;;",
"     </li>",
"     <li>",
"      Apo-Keto&reg;;",
"     </li>",
"     <li>",
"      Ketoprofen SR;",
"     </li>",
"     <li>",
"      Ketoprofen-E;",
"     </li>",
"     <li>",
"      Nu-Ketoprofen;",
"     </li>",
"     <li>",
"      Nu-Ketoprofen-E;",
"     </li>",
"     <li>",
"      PMS-Ketoprofen;",
"     </li>",
"     <li>",
"      PMS-Ketoprofen-E",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702347",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ketoprofen or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10782 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-6167F63EEA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30645=[""].join("\n");
var outline_f29_59_30645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185916\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029858\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029860\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029859\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029864\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029865\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029867\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029862\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029863\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029868\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029869\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=related_link\">",
"      Ketoprofen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_59_30646="Lorcaserin: Drug information";
var content_f29_59_30646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lorcaserin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/47/7925?source=see_link\">",
"    see \"Lorcaserin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14593997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anorexiant;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       2C",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15668900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Weight management:",
"     </b>",
"     Oral: 10 mg twice daily (maximum: 10 mg twice daily); evaluate response by week 12; if patient has not lost &ge;5% of baseline body weight, discontinue therapy",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15668904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15668901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Renal function was estimated in studies using ideal body weight (IBW) with the Cockcroft-Gault formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute): Use with caution; serum concentrations and half-life of major metabolites are increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ESRD: Use is not recommended; hemodialysis does not remove lorcaserin or M1 metabolite",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15668902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh score 5-9): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Use with caution (has not been studied); undergoes extensive hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15668754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14584098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Belviq&reg;: FDA approved June 2012; anticipated availability is first quarter of 2013. Consult prescribing information for additional information. The DEA is currently evaluating Belviq&reg; as a controlled substance, and the scheduling category is being determined.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15668905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14584097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity, in patients with either an initial body mass index (BMI) of &ge;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     an initial BMI of &ge;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     and at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15668752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lorcaserin hydrochloride may be confused with loratadine hydrochloride (Claritin&reg;) and losartan (Cozaar&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lorcaserin may be confused with Lotensin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The U.S. Drug Enforcement Administration (DEA) is currently evaluating Belviq&reg; as a controlled substance, and the scheduling category is being determined.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15668861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (15% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (diabetic patients 29%; severe: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphocytes decreased (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (14%), nasopharyngitis (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (5%), hypertension (5%), valvulopathy (at 1 year: 2.4%; placebo: 2.0%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (7% to 9%), fatigue (7%), anxiety (4%), insomnia (4%), depression (2% to 3%; placebo: 2%), cognitive impairment (2%), psychiatric disorders (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Diabetes mellitus exacerbation (3%), prolactin increased (&lt;2 x ULN: 7%; 2 x ULN: 2%; 5 x ULN: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (8% to 9%), diarrhea (7%), constipation (6%), xerostomia (5%), vomiting (4%), gastroenteritis (3%), toothache (3%), appetite decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (7% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hemoglobin decreased (10%), neutrophils decreased (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms (5%), musculoskeletal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eye disorders (5%; diabetic patients 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (4% to 8%), oropharyngeal pain (4%), sinus congestion (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Seasonal allergy (3%), stress (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening):  Bradycardia, dissociation, euphoria, serotonin syndrome, suicidal ideation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15668758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15668759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: May cause confusion, somnolence, fatigue, and cognitive impairment (difficulty with concentration/attention/memory); patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hematological effects: Rare WBC and RBC count decreases (including leukopenia, lymphopenia, neutropenia, anemia, decreases in hematocrit and hemoglobin) have been observed. Consider monitoring CBC periodically during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperprolactinemia: Increased prolactin levels may occur; in general, increases are moderate (&le;2 x ULN), although prolactin elevations (5 x ULN) have been reported rarely. Obtain prolactin levels if signs or symptoms of hyperprolactinemia occur (eg, galactorrhea, gynecomastia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Priapism: May occur with use; men with erections &gt;4 hours should immediately discontinue lorcaserin and seek emergency medical attention to avoid irreversible damage to erectile tissue. Use with caution in men with conditions that increase the risk for priapism (eg, sickle cell anemia, multiple myeloma, leukemia) or men with anatomical penis deformities (eg, angulation, cavernosal fibrosis, Peyronie's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Primary pulmonary hypertension (PPH): PPH is a rare and frequently fatal pulmonary disease, which has been reported in patients receiving other centrally acting, serotonergic weight loss agents. Available data from clinical trials are inadequate to determine if lorcaserin increases the risk for pulmonary hypertension (due to the low incidence of PPH occurring in the general population); however, a theoretical risk cannot be excluded.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychiatric disorders: Agents affecting the CNS have been associated with depression and suicidal ideation; monitor patients closely during use; discontinue for suicidal thoughts or behaviors. In short-term studies, euphoria, hallucinations, and dissociation have been observed with lorcaserin at supratherapeutic doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Serotonin syndrome (SS)/neuroleptic malignant syndrome (NMS)-like reactions: SS and NMS-like reactions have occurred with serotonergic agents such as lorcaserin, particularly when used in combination with other serotonergic agents (eg, triptans, SNRIs, SSRIs, TCAs, bupropion, St John&rsquo;s wort, tryptophan), agents that impair metabolism of serotonin (eg, MOA inhibitors, dextromethorphan, tramadol, lithium), or antidopaminergic agents (eg, antipsychotics). Identification and differentiation of SS (eg, tremor, myoclonus, agitation) and more severe NMS-like reactions (eg, hyperthermia, muscle rigidity, autonomic instability, mental status changes) may be complex; monitor patients closely for either syndrome. Discontinue treatment (and any concomitant serotonergic and/or antidopaminergic agents) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Valvular heart disease: Cardiac valvular disease has been associated with the use of agents exhibiting potent 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     agonist activity (eg, cabergoline, fenfluramine [not currently on the U.S. market], dexfenfluramine [not currently on the U.S. market]). Cardiac valvular disease is believed to result from activation of 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     receptors in interstitial cardiac cells. Lorcaserin has greater affinity for 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     receptors compared to 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     receptors (at therapeutic doses). However, a slight increase in incidence of regurgitant cardiac valve disease (mitral and/or aortic) has been observed with lorcaserin compared to placebo in some clinical trials (pooled RR: 1.16; 95% CI: 0.81-1.67). The incidence observed in both groups was low, making it difficult to ascertain the risk of valvular disease with lorcaserin therapy based on available data. Evaluate patients if signs/symptoms of valvular heart disease (eg, dyspnea, dependent edema, heart failure, new onset cardiac murmur) arise during therapy; consider discontinuing therapy if present. Use has not been studied in patients with hemodynamically-significant valvular heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with bradycardia or heart block (second or third degree); bradycardia has been observed rarely with use. Use with caution in patients with heart failure (has not been studied); data suggests that 5HT",
"     <sub>",
"      2B",
"     </sub>",
"     receptors may be overexpressed in heart failure which could potentially increase the risk of valvular heart disease developing from use. Effect of lorcaserin on cardiovascular morbidity and mortality has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use with caution in patients with type 2 diabetes mellitus; weight loss from therapy may result in decreased requirements of antidiabetic agents and an increased risk of hypoglycemia; monitor blood glucose. Hypoglycemia has been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (not studied). Lorcaserin undergoes extensive hepatic metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Serum concentrations and principal metabolite (M1 and M5) half-lives are increased in renal impairment. Use is not recommended in patients with severe impairment or end stage renal disease. Use with caution in patients with moderate renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Potent 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     receptor agonists: Do not use lorcaserin in combination with potent serotonergic and dopaminergic agents that are potent 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     receptor agonists (eg, cabergoline) due to the risk for cardiac valvulopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Serotonergic agents or antidopaminergic agents: Since lorcaserin is a serotonergic agent, there is a potential for serotonin syndrome to occur if used concomitantly with other serotonergic agents or antidopaminergic agents (eg, antipsychotics); concurrent use should be avoided. If concomitant use cannot be avoided, coadminister with extreme caution, and closely monitor patients, particularly during treatment initiation. Discontinue use immediately if signs/symptoms of serotonin syndrome symptoms or NMS-like reactions develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Weight loss agents: Concomitant use of lorcaserin with other agents intended for weight loss (eg, phentermine, orlistat, OTC, or herbal preparations) has not been evaluated; safety and efficacy of coadministration with other weight loss agents are unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Abuse potential: Incidences of euphoria and hallucinations were low (&lt;1%) in clinical trials of obese patients with durations up to 52 weeks; however, in abuse potential studies of recreational drug abusers and in short term studies of healthy patients using supratherapeutic doses, the incidences of hallucinations and  euphoria were higher (&gt;10%). Data suggest lorcaserin may produce psychic dependence. Physical dependence or a withdrawal syndrome has not been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Pharmacotherapy for weight loss should be used in conjunction with a comprehensive weight management program including diet and exercise. Discontinue if significant weight loss has not occurred (ie, &lt;5% within the first 12 weeks of treatment).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15896883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15896881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May enhance the serotonergic effect of Lorcaserin. This could result in serotonin syndrome. Management: Seek alternatives to this combination when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Lorcaserin may enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Lorcaserin may enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15668755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15668756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse fetal effects were observed in some animal reproduction studies. Due to the fact that weight loss during pregnancy offers no clinical benefit, lorcaserin is contraindicated in pregnancy. Obese and overweight women should be encouraged to participate in weight reduction programs prior to attempting pregnancy; weight gain during pregnancy should be determined by their prepregnancy BMI and current guidelines (ADA, 2009; IOM, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15668757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/ not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15669542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Lorcaserin may alter maternal serum prolactin concentrations. It is not known if lorcaserin is excreted into breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Weight-loss therapy is generally not recommended for lactating women. Weight-loss programs which include physical activity and nutrition components should be discussed at the 6-week postpartum visit (ADA, 2009; IOM, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15668919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weight, waist circumference; CBC (periodically during use); blood glucose (in diabetics); prolactin levels (if galactorrhea, gynecomastia or other signs/symptoms of hyperprolactinemia arise); monitor for depression or suicidal thoughts/behavior; signs/symptoms of SS/NMS-like reaction; signs/symptoms of valvular heart disease (dyspnea, dependent edema)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15668881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lorcaserin is believed to activate serotonin 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     receptors, which stimulate pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus, leading to increased alpha-melanocortin stimulating hormone release at melanocortin-4 receptors and resulting in satiety and decreased food intake. At recommended doses, lorcaserin has greater affinity for 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     receptors compared to other 5-HT receptor subtypes (including 5-HT2A and 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     ), the 5-HT receptor transporter, and 5-HT reuptake sites (Hurren, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15668883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes to the CNS and cerebrospinal fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~70% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive hepatic metabolism, via multiple enzymatic pathways, producing two major metabolites (inactive), lorcaserin sulfamate (M1) and N-carbamoyl glucuronide lorcaserin (M5), as well as minor metabolites (glucuronide and sulfate conjugates)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (92%, as metabolites); feces (2%, as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Dietetic Association; American Society of Nutrition, Siega-Riz AM, et al, \"Position of the American Dietetic Association and American Society for Nutrition: Obesity, Reproduction, and Pregnancy Outcomes,\"",
"      <i>",
"       J Am Diet Assoc",
"      </i>",
"      , 2009, 109(5):918-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30646/abstract-text/19412993/pubmed\" id=\"19412993\" target=\"_blank\">",
"        19412993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fidler MC, Sanchez M, Raether B, et al, &ldquo;A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2011, 96(10):3067-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30646/abstract-text/21795446/pubmed\" id=\"21795446\" target=\"_blank\">",
"        21795446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hurren KM and Berlie HD, &ldquo;Lorcaserin: An Investigational Serotonin 2C Agonist for Weight Loss,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(21):2029-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30646/abstract-text/22011982/pubmed\" id=\"22011982\" target=\"_blank\">",
"        22011982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine) and NRC (National Research Council), \"Weight Gain During Pregnancy: Reexamining the Guidelines,\" Washington, DC: The National Academies Press, 2009. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30646/abstract-text/20669500/pubmed\" id=\"20669500\" target=\"_blank\">",
"        20669500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin CK, Redman LM, Zhang J, et al, &ldquo;Lorcaserin, a 5-HT(2C) Receptor Agonist, Reduces Body Weight By Decreasing Energy Intake Without Influencing Energy Expenditure,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2011, 96(3):837-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30646/abstract-text/21190985/pubmed\" id=\"21190985\" target=\"_blank\">",
"        21190985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Neil PM, Smith SR, Weissman NJ, et al, &ldquo;Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study,&rdquo;",
"      <i>",
"       Obesity",
"      </i>",
"      , 2012, 20(7):1426-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30646/abstract-text/22421927/pubmed\" id=\"22421927\" target=\"_blank\">",
"        22421927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SR, Weissman NJ, Anderson CM, et al, &ldquo;Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(3):245-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/59/30646/abstract-text/20647200/pubmed\" id=\"20647200\" target=\"_blank\">",
"        20647200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85674 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30646=[""].join("\n");
var outline_f29_59_30646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14593997\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668900\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668904\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668901\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668902\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668754\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14584098\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668905\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14584097\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668752\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668861\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668758\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668759\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896883\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896881\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668755\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668756\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668757\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15669542\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668919\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668881\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668883\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85674|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/47/7925?source=related_link\">",
"      Lorcaserin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_59_30647="Modified Epleys Right";
var content_f29_59_30647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Modified Epley's maneuver for self-treatment of benign positional vertigo (right)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This maneuver should be carried out three times a day. Repeat this daily until you are free from positional vertigo for 24 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Http://www.charite.de/ch/neuro/englishL.htm",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30647=[""].join("\n");
var outline_f29_59_30647=null;
var title_f29_59_30648="Candidal intertrigo";
var content_f29_59_30648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Candidal intertrigo",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30648/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30648/contributors\">",
"     Eva R Parker, MD, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30648/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30648/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30648/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30648/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/59/30648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intertrigo is any infectious or noninfectious inflammatory condition of two closely opposed skin surfaces (intertriginous area). While it may result from the overgrowth of microorganisms including bacteria, the term often refers to a process that is due to a superficial infection with Candida species. Candida intertrigo is the most common cutaneous candidal infection of hair-bearing skin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"intertrigo\" in this topic refers to Candida intertrigo, the diagnosis and treatment of which will be reviewed here. Tinea cruris due to dermatophyte infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The warm, moist environment of the skin folds is ideal for the growth of Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/2\">",
"     2",
"    </a>",
"    ]. The risk of infection is increased by specific factors that increase skin friction, increase moisture within folds, or interfere with the immune response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    promote fungal overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that may increase skin friction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Clothing (especially tightly fitting) that chafes skin",
"     </li>",
"     <li>",
"      Activities that promote skin-on-skin rubbing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that increase moisture include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Occlusive clothing",
"     </li>",
"     <li>",
"      Hyperhidrosis",
"     </li>",
"     <li>",
"      Incontinence",
"     </li>",
"     <li>",
"      Occupational exposure to moisture, such as wearing rubber gloves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that interfere with the immune response or promote fungal overgrowth include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Topical and systemic glucocorticoids",
"     </li>",
"     <li>",
"      Antibiotics, particularly when chronically or repeatedly administered",
"     </li>",
"     <li>",
"      HIV",
"     </li>",
"     <li>",
"      Chemotherapy",
"     </li>",
"     <li>",
"      Immunosuppressant medications",
"     </li>",
"     <li>",
"      Occupational exposure to sugar, such as in bakers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recalcitrant candidal intertrigo without an obvious explanation raises the possibility of underlying or undiagnosed endocrinopathy, malnutrition, malignancy, or HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida is a unicellular, dimorphic fungus that produces 3 to 7 &micro;m budding yeast cells called blastophores and 3 to 5 &micro;m septate hyphae and pseudohyphae (elongated, filamentous cells connected end to end) in tissue or fluid exudates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. In cultures incubated at 20&ordm;C, pseudohyphae and chlamydospores are formed. Cultures incubated at 37&ordm;C demonstrate germ tube formation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are more than 100 species of Candida, Candida albicans is the most frequent pathogen isolated from lesions of Candida intertrigo. Other pathogenic species include tropicalis, krusei, glabrata, parapsilosis, lusitaniae, guilliermondii, kefyr (pseudotropicalis), and stellatoidea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Candida albicans is a commensal organism considered to be normal flora of the gastrointestinal tract, vagina, and oral cavity. However, Candida albicans can become an opportunistic infection when host defenses, physiology, the local microenvironment, or normal resident flora become altered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-lymphocyte mediated immunity is the primary defense mechanism against candidal infection in human hosts. Key elements of this mechanism are phagocytosis and the killing of yeast organisms by macrophages and neutrophils. C3b surface receptors on neutrophils and macrophages deposit C3b opsonins onto the yeast which signal for phagocytosis of the organism and subsequent intracellular killing via oxidative and nonoxidative mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,8,10\">",
"     1,8,10",
"    </a>",
"    ]. In addition, secretory and circulating antibodies are also thought to contribute to host defenses but the humoral immune system appears to play only a minor role in protecting from yeast infection.",
"   </p>",
"   <p>",
"    Patients with either T-lymphocyte defects, as in HIV infection, and patients with neutropenia due to chemotherapy or altered neutrophil function, as in diabetes mellitus, have increased susceptibility to cutaneous infection with Candida.",
"   </p>",
"   <p>",
"    Mechanical maintenance of skin integrity and epidermal proliferation and turnover serve essential protective functions. Local factors such as trauma, occlusion, and maceration that damage host tissue are known to enhance Candida colonization and adhesion. Normal cutaneous bacterial flora provide additional host protection by competing for nutrients, occupying epithelial adhesion sites, and producing metabolic by-products that are toxic to yeast organisms. In summary, a failure in the host defense system including disruption of the skin's integrity by maceration and abrasion, impaired cellular immunity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alteration of normal skin flora facilitates cutaneous infection by Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,8,11\">",
"     1,8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Candida species possess a wide range of potential virulence factors that are differentially expressed depending on the site of infection, environmental conditions, and host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/12\">",
"     12",
"    </a>",
"    ]. While much remains to be elucidated with respect to its virulence properties, research has established cell morphology, adhesion factors, phenotypic switching, and the selective expression of 10 SAP genes that encode extracellular secreted aspartic proteinases (SAP) as key elements of Candida albicans pathogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adhesion to and colonization of the epidermis result from candidal surface glycoproteins binding to arginine-glycine-aspartate sequences on collagen, laminin, and extracellular matrix glycoproteins. Glycoproteins on the surface of the yeast can also interact with epidermal membrane glycoproteins in a lecitin-like manner to establish adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/11\">",
"     11",
"    </a>",
"    ]. In response to environmental stimuli at the site of infection, Candida undergoes a phenotypic change from budding yeast to hyphal and germ tube forms with resultant filamentous or mycelial growth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Production of the various SAP, which possess proteolytic activity against keratin, collagen, laminin, fibronectin, and immunoglobulins including secretory IgA, then allow hyphal invasion of the corneal layer.",
"   </p>",
"   <p>",
"    Subsequent deeper invasion occurs both by further proteolytic degradation of host tissue and by thigmotropism, a mechanism of contact sensing utilized by Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Penetration into the epidermis by hyphae is further enhanced by phospholipases localized to the hyphal tips that are responsible for direct injury to host cell membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of invasion, epidermal proliferation and phagocytosis of hyphae by keratinocytes occur [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/11\">",
"     11",
"    </a>",
"    ]. An inflammatory response is triggered and maintained, in part because mannin and beta-glycan, proteins contained within the fungal cell wall, stimulate lymphocyte proliferation, activate complement via the alternative pathway, and induce neutrophil chemotaxis. These proteins also trigger keratinocytes to produce the proinflammatory cytokines interleukin (IL)-6 and IL-8 through activation of Toll-like receptor 2. In addition, candidal SAP activate the release of other proinflammatory cytokines including IL-1 alpha, IL&ndash;1 beta, tumor necrosis factor-alpha, and granulocyte macrophage colony-stimulating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,11,19-22\">",
"     1,11,19-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical locations for intertrigo include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inguinal folds (",
"      <a class=\"graphic graphic_picture graphicRef72073 \" href=\"UTD.htm?29/34/30246\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Axillae (",
"      <a class=\"graphic graphic_picture graphicRef78179 \" href=\"UTD.htm?18/15/18675\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Scrotum",
"     </li>",
"     <li>",
"      Intergluteal folds",
"     </li>",
"     <li>",
"      Inframammary folds (",
"      <a class=\"graphic graphic_picture graphicRef71145 \" href=\"UTD.htm?17/44/18114\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Web spaces of the toes and fingers (",
"      <a class=\"graphic graphic_picture graphicRef79187 \" href=\"UTD.htm?24/7/24691\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abdominal folds, particularly beneath a pannus",
"     </li>",
"     <li>",
"      Redundant skin at the corners of the mouth in older individuals (perl&egrave;che)",
"     </li>",
"     <li>",
"      Neck folds in infants (",
"      <a class=\"graphic graphic_picture graphicRef62523 \" href=\"UTD.htm?27/43/28338\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intertrigo presents as erythematous, macerated plaques and erosions with delicate peripheral scaling and erythematous satellite papulopustules. The pustules are easily ruptured, leaving an erythematous base with a surrounding collarette of epidermis. The lesions are often pruritic and may be painful if significant skin breakdown accompanies the infection (",
"    <a class=\"graphic graphic_picture graphicRef80146 \" href=\"UTD.htm?0/16/257\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,2,4,23\">",
"     1,2,4,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several unique forms of Candida intertrigo exist and include diaper dermatitis and erosio interdigitalis blastomycetica.",
"   </p>",
"   <p>",
"    Candidal diaper dermatitis occurs in 4 to 6 percent of term infants with a peak incidence at three to four months of age, but can occur at any age in patients with incontinence. The dermatitis is a result of cutaneous colonization by yeast from the patient's gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/5\">",
"     5",
"    </a>",
"    ]. Chronic occlusion by wet diapers predisposes to infection, which initially begins in the perianal area with subsequent extension to the perineum and inguinal creases. The lesions appear as erythematous macerated plaques with satellite pustules typical of intertrigo (",
"    <a class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \" href=\"UTD.htm?35/41/36501\">",
"     picture 7A-B",
"    </a>",
"    ). Persistent candidal diaper rash in young children may be a sign of type 1 diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link\">",
"     \"Overview of diaper dermatitis in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erosio interdigitalis blastomycetica, interdigital candidiasis of the hands and feet, specifically involving the third and fourth interspaces, presents as erythema and maceration with peripheral desquamation of the web space (",
"    <a class=\"graphic graphic_picture graphicRef79187 \" href=\"UTD.htm?24/7/24691\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. This is most often observed on the hands due to occupational exposure to moisture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sugar and is commonly seen in bakers, confectioners, fruit handlers, bartenders, housekeepers, and any person wearing gloves for prolonged periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. Toe web intertrigo is a risk factor for the development of lower extremity cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of intertrigo is generally made clinically, based on the typical appearance and distribution of lesions. However, the diagnosis can be confirmed by potassium hydroxide (KOH) examination (",
"    <a class=\"graphic graphic_picture graphicRef79879 \" href=\"UTD.htm?27/37/28242\">",
"     picture 8",
"    </a>",
"    ) or culture of skin scrapings (",
"    <a class=\"graphic graphic_picture graphicRef50344 \" href=\"UTD.htm?40/12/41167\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H9#H9\">",
"     \"Dermatologic procedures\", section on 'Fungal culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct microscopic examination of skin scrapings treated with KOH reveals typical oval budding yeasts with septate hyphae and pseudohyphae (elongated, filamentous cells connected end to end) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,4,23\">",
"     1,4,23",
"    </a>",
"    ]. In addition, growth on either bacterial media or Sabouraud's dextrose agar treated with antibiotics yields whitish mucoid colonies after two to five days incubation at room temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although rarely necessary, cutaneous biopsy may also be performed to confirm the diagnosis. On routine hematoxylin and eosin staining (H&amp;E), parakeratotic scale with underlying subcorneal pustules is observed. The epidermis is spongiotic with neutrophil exocytosis. Within the dermis, prominent edema and a perivascular and interstitial infiltrate of neutrophils are characteristic. Periodic acid-Schiff (PAS) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver stains allow visualization of the yeast organisms within the stratum corneum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/17,26\">",
"     17,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common or important conditions that may mimic intertrigo include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tinea cruris, which generally begins on the thigh opposite the scrotum while intertrigo affects the skin on the thigh and the scrotum simultaneously (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"       \"Dermatophyte (tinea) infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atopic dermatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Contact dermatitis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of dermatitis\", section on 'Contact dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seborrheic dermatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of dermatitis\", section on 'Seborrheic dermatitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=see_link&amp;anchor=H43690682#H43690682\">",
"       \"Seborrheic dermatitis in adolescents and adults\", section on 'Seborrheic dermatitis of the trunk and intertriginous areas'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inverse psoriasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Inverse psoriasis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Erythrasma (",
"      <a class=\"graphic graphic_picture graphicRef51713 \" href=\"UTD.htm?42/36/43587\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bacterial intertrigo secondary to Staphylococcus aureus or group A streptococcus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"       \"Cellulitis and erysipelas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Herpes simplex (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mycosis fungoides (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extramammary Paget disease (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link&amp;anchor=H12#H12\">",
"       \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\", section on 'Extramammary Paget disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Familial benign pemphigus (Hailey-Hailey disease) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link&amp;anchor=H35#H35\">",
"       \"Differential diagnosis of vulvar lesions\", section on 'Hailey-Hailey'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Glucagonoma syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link\">",
"       \"Glucagonoma and the glucagonoma syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Langerhans cell histiocytosis, which should be considered in children who appear to have recalcitrant diaper area dermatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is relatively little evidence from controlled trials addressing the best therapy for intertrigo. However, the following basic treatment approach to intertrigo is generally successful [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/6,23\">",
"     6,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Address predisposing factors",
"     </li>",
"     <li>",
"      Treat with topical antifungals",
"     </li>",
"     <li>",
"      Use drying agents after an adequate course of antifungals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other treatments that may be indicated in more severe cases include topical corticosteroids in combination with antifungal therapy and oral antifungals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component to successful treatment is the amelioration of predisposing factors and underlying conditions, such as diabetes mellitus, that may contribute to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When obesity is a contributing factor, weight loss should be encouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with chronic inframammary intertrigo due to large pendulous breasts have benefited from reduction mammoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/27\">",
"     27",
"    </a>",
"    ]; however, such surgery is rarely performed just for this indication.",
"   </p>",
"   <p>",
"    In addition, skin maceration and irritation from chronic incontinence in elderly patients can contribute to the development of intertrigo in the groin area. A structured skin care routine and the use of high quality absorbent hygiene products can ameliorate skin breakdown and reduce the risk of Candida infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Topical antifungal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main classes of topical antifungals employed in the treatment of intertrigo are the polyene and azole families. Topical creams are recommended for twice daily use until symptoms resolve. They may be applied twice weekly thereafter to prevent recurrence or an antifungal powder may be used for this purpose (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Drying agents'",
"    </a>",
"    below). The most commonly used are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    (polyene), miconazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/56/4995?source=see_link\">",
"     econazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23731?source=see_link\">",
"     sertaconazole",
"    </a>",
"    (azoles). Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7827?source=see_link\">",
"     oxiconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/46/2787?source=see_link\">",
"     sulconazole",
"    </a>",
"    have activity against Candida species, this activity is relatively weaker than the other azoles. Other antifungal options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8643?source=see_link\">",
"     naftifine",
"    </a>",
"    (allylamines),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/61/31699?source=see_link\">",
"     butenafine",
"    </a>",
"    (a benzylamine), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    (a hydroxypyridone) (",
"    <a class=\"graphic graphic_table graphicRef76148 \" href=\"UTD.htm?19/3/19517\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. There are few data from controlled trials comparing the treatment of intertrigo with different topical antifungal agents.",
"   </p>",
"   <p>",
"    One study found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    to have better in vitro activity against Candida than many of the azoles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/37\">",
"     37",
"    </a>",
"    ]. Additionally, while most topical antifungal agents have the added benefit of also possessing mild antiinflammatory properties, ciclopirox in particular has strong activity against both gram-positive and gram-negative bacteria, which often coexist with candida in intertriginous zones [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/23,31,38\">",
"     23,31,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The topical antifungal agents are generally very well tolerated with rare adverse events that consist primarily of burning, irritation, pruritus, erythema, or allergic contact dermatitis at the site of application [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest selecting a topical antifungal based on availability, cost, and provider familiarity with the agent (",
"    <a class=\"graphic graphic_table graphicRef76148 \" href=\"UTD.htm?19/3/19517\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drying agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical drying agents also play an important role in the treatment of intertrigo, as moisture and maceration are key aspects of the pathogenesis of this disorder.",
"   </p>",
"   <p>",
"    Various agents have been employed to keep the skin folds dry, clean, and cool. These include antifungal powders (including miconazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12146?source=see_link\">",
"     undecylenic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/61/28627?source=see_link\">",
"     tolnaftate",
"    </a>",
"    , and 12 percent benzoic acid),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/7/127?source=see_link\">",
"     aluminum sulfate calcium acetate",
"    </a>",
"    solution (Domeboro's solution),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=see_link\">",
"     gentian violet",
"    </a>",
"    solution, carbol-fuchsin solution (Castellani&rsquo;s paint), and antiseptic drying agents such as potassium permanganate solution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/6,23,39\">",
"     6,23,39",
"    </a>",
"    ]. Talcum powder may also be employed as a drying agent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/6,23,40\">",
"     6,23,40",
"    </a>",
"    ]; however, its use in the genital area of women has been associated with an increased risk of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/41\">",
"     41",
"    </a>",
"    ]. Corn starch is an inexpensive alternative that was found in one study to effectively protect against frictional injury without enhancing the growth of yeast [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although antifungal powders may be used as monotherapy for both their antifungal and drying properties, because of decreased skin penetration their antifungal effectiveness is generally less than that of the equivalent medication in cream or ointment form.",
"   </p>",
"   <p>",
"    Drying agents are typically used after an adequate course of antifungal therapy has been completed to help maintain a dry intertriginous environment and minimize the risk of maceration and reinfection. Patients at high risk for recurrence of intertrigo should use a drying powder indefinitely.",
"   </p>",
"   <p>",
"    Powder drying agents cannot be applied simultaneously with antifungal creams or ointments as this will result in a sticky paste. If used together the preparations should be applied several hours apart. If there is considerable maceration or weeping at the time of diagnosis, compresses with a drying solution, such as Domeboro's, may be applied for 10 to 15 minutes twice daily, followed by the application of an antifungal cream.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although low potency topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ) may be used in conjunction with antifungal therapy to treat associated pruritus, pain, and burning [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/1\">",
"     1",
"    </a>",
"    ], these symptoms generally respond quickly to antifungal therapy alone. Thus the use of topical corticosteroids is usually not necessary. Moderate and high potency corticosteroid preparations should be avoided.",
"   </p>",
"   <p>",
"    The topical combination",
"    <span class=\"nowrap\">",
"     glucocorticoid/antifungal",
"    </span>",
"    medication Lotrisone contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate, a Class II topical corticosteroid when in cream form and a class III glucocorticoid when in a lotion-based vehicle. It should not be used in intertriginous zones, but is often misused to treat intertrigo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/42\">",
"     42",
"    </a>",
"    ]. However, topical combination preparations containing 1%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/38/21091?source=see_link\">",
"     iodoquinol",
"    </a>",
"    with 2%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    acetate may be safely applied in intertriginous zones for a short time period and may be an effective alternative in treating candida intertrigo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oral antifungal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic antifungal medications are rarely necessary for the treatment of intertrigo. However, in patients with severe or recalcitrant infection, oral therapy with an azole may be beneficial, with a response rate of 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/23,44-46\">",
"     23,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with an oral agent should generally only be used when a patient has failed topical therapy or has a particularly severe presentation.",
"   </p>",
"   <p>",
"    Agents typically used include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/23,44,47-50\">",
"     23,44,47-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      50 to 100 mg daily or 150 mg weekly",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      200 mg twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      200 mg daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typical systemic antifungal doses for children include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once, then 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      5 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in two doses",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      3.3 to 6.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day given as a single daily dose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapy is generally continued for two to six weeks or until signs and symptoms have resolved.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     Griseofulvin",
"    </a>",
"    , however, has no activity against Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/23,47\">",
"     23,47",
"    </a>",
"    ]. Although oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    has shown efficacy in the treatment of onychomycosis secondary to Candida species and has demonstrated fungistatic activity against Candida albicans and Candida parapsilosis, it is uncertain whether it is active against cutaneous candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/32,48,52-54\">",
"     32,48,52-54",
"    </a>",
"    ]. Thus, we do not consider terbinafine a first-line oral therapy for intertrigo despite its utility as a topical agent.",
"   </p>",
"   <p>",
"    Common adverse effects from oral antifungal drugs include diarrhea, dyspepsia, nausea, abdominal pain, headache, and morbilliform rash [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/47\">",
"     47",
"    </a>",
"    ]. Asymptomatic, mild elevations (one and a half to two times normal) in transaminases may be observed on routine laboratory monitoring in approximately 3 to 4 percent of patients taking an oral antifungal medication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/55\">",
"     55",
"    </a>",
"    ]. Clinically significant hepatotoxicity has also been described with these agents, but is fortunately a rare occurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug interactions are a frequent issue with oral antifungal agents, many of which affect the cytochrome P450 mixed function oxidase enzymes. It is important that prescribers carefully review patient medication lists for potential drug-drug interactions whenever prescribing these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Azole resistance has begun to emerge, especially in HIV patients receiving long-term suppressive treatment. In addition, Candida krusei, Candida glabrata, and Candida tropicalis are often intrinsically resistant to oral azole therapy, mainly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. In general, long-term suppressive therapy in high risk patients is discouraged due to the potential for clinical tolerance, microbial resistance, and subsequent colonization with the more resistant Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents are sometimes used for the treatment of intertrigo. The topical calcineurin inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    appeared to show benefit in a small uncontrolled trial of treatment in patients with intertrigo due to noninfectious inflammatory etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/56\">",
"     56",
"    </a>",
"    ]. It might also be expected to provide benefit in those patients with candida intertrigo for whom a topical antiinflammatory agent is indicated but who are unable to use topical corticosteroids.",
"   </p>",
"   <p>",
"    Although heat lamps are occasionally recommended to assist with drying areas of intertrigo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30648/abstract/57\">",
"     57",
"    </a>",
"    ], we know of no good evidence demonstrating this to be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intertrigo is any infectious or noninfectious inflammatory condition of two closely opposed skin surfaces (intertriginous area). While it may result from the overgrowth of microorganisms including bacteria, the term often refers to a process that is due to a superficial infection with Candida species, and \"intertrigo\" in this topic refers to candidal intertrigo (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The risk of intertrigo is increased by factors that increase skin friction and moisture, by factors that decrease the immune response, and by factors that promote fungal overgrowth. These include occlusive or chafing clothing, obesity, diabetes, and HIV infection (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and risk factors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Typical locations for intertrigo include the groin, axillae, inframammary and abdominal folds, and the web spaces of fingers and toes. Intertrigo presents as erythematous, macerated plaques and erosions with delicate peripheral scaling and erythematous satellite papulopustules. It is frequently pruritic (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Intertrigo is generally diagnosed clinically based on its typical appearance, however the diagnosis can be confirmed by KOH examination and culture of skin scrapings (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Treatment should include amelioration of predisposing factors (eg, avoidance of occlusive clothing) and underlying conditions (eg, improving blood sugar control) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Predisposing factors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Initial treatment in most patients involves a topical antifungal cream. We suggest choosing a topical antifungal cream based on availability, cost, and provider familiarity with the agent (",
"      <a class=\"graphic graphic_table graphicRef76148 \" href=\"UTD.htm?19/3/19517\">",
"       table 1",
"      </a>",
"      ); (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Topical antifungal agents'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      After completion of an appropriate course of antifungal therapy, patients should use a drying agent, such as an antifungal powder, to help maintain a dry intertriginous environment and minimize the risk of maceration and reinfection; patients at high risk of reinfection should use a drying agent on an ongoing basis (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Drying agents'",
"      </a>",
"      above). Patients at high risk of reinfection may also benefit from applying a topical antifungal cream twice weekly (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Topical antifungal agents'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with significant itching and irritation may be treated with a low potency topical corticosteroid (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 2",
"      </a>",
"      ) in conjunction with antifungal therapy, however this is not usually necessary (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Topical corticosteroids'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest that adults with severe or recalcitrant disease be treated for two to six weeks with an oral antifungal such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      200 mg daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      50 to 100 mg daily, or fluconazole 150 mg weekly (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Oral antifungal agents'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Klenk AS, Martin AG, Heffernan MP. east infections: candidiasis, pityriasis (tinea) versicolor. In: Dermatology in General Medicine, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, New York 2003. p.2006.",
"    </li>",
"    <li>",
"     Yaar, M, Gilchrest, BA. Aging of skin. In: Fitzpatrick's Dermatology in General Medicine, Freedberg, IM, Eisen, AZ, Wolff, K, et al (Eds), McGraw-Hill, New York 2003. p.1386.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/3\">",
"      Garc&iacute;a Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol 2002; 3:497.",
"     </a>",
"    </li>",
"    <li>",
"     Sobera, JO, Elewski BE. Fungal Diseases. In: Dermatology, Bolognia, JL, Jorizzo, JL, Rapini, RP (Eds), Mosby, London 2003. p.1171.",
"    </li>",
"    <li>",
"     Friedlander, SF, Rueda, M, Chen, BK, Caceres-Rios, HW. Fungal, protozoal, and helminthic infections. In: Pediatric Dermatology, Schachner, LA, Hansen RC (Eds), Mosby, Edinburgh 2003. p.1093.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/6\">",
"      Hay RJ. The management of superficial candidiasis. J Am Acad Dermatol 1999; 40:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/7\">",
"      Jautov&aacute; J, Baloghov&aacute; J, Dorko E, et al. Cutaneous candidosis in immunosuppressed patients. Folia Microbiol (Praha) 2001; 46:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/8\">",
"      Hay RJ. Yeast infections. Dermatol Clin 1996; 14:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/9\">",
"      Hay RJ. Antifungal therapy of yeast infections. J Am Acad Dermatol 1994; 31:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/10\">",
"      Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr Opin Microbiol 2002; 5:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/11\">",
"      Odds FC. Pathogenesis of Candida infections. J Am Acad Dermatol 1994; 31:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/12\">",
"      Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001; 147:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/13\">",
"      Schaller M, Schackert C, Korting HC, et al. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol 2000; 114:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/14\">",
"      Calderone RA. Host-parasite relationships in candidosis. Mycoses 1989; 32 Suppl 2:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/15\">",
"      Costa CR, Jesu&iacute;no RS, de Aquino Lemos J, et al. Effects of antifungal agents in sap activity of Candida albicans isolates. Mycopathologia 2010; 169:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/16\">",
"      Bahn YS, Sundstrom P. CAP1, an adenylate cyclase-associated protein gene, regulates bud-hypha transitions, filamentous growth, and cyclic AMP levels and is required for virulence of Candida albicans. J Bacteriol 2001; 183:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/17\">",
"      Scherwitz C. Ultrastructure of human cutaneous candidosis. J Invest Dermatol 1982; 78:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/18\">",
"      Mukherjee PK, Seshan KR, Leidich SD, et al. Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. Microbiology 2001; 147:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/19\">",
"      Cassone A, Marconi P, Bistoni F. Cell wall of Candida albicans and host response. Crit Rev Microbiol 1987; 15:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/20\">",
"      Beaus&eacute;jour A, Grenier D, Goulet JP, Deslauriers N. Proteolytic activation of the interleukin-1beta precursor by Candida albicans. Infect Immun 1998; 66:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/21\">",
"      Schaller M, Mailhammer R, Korting HC. Cytokine expression induced by Candida albicans in a model of cutaneous candidosis based on reconstituted human epidermis. J Med Microbiol 2002; 51:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/22\">",
"      Li M, Chen Q, Shen Y, Liu W. Candida albicans phospholipomannan triggers inflammatory responses of human keratinocytes through Toll-like receptor 2. Exp Dermatol 2009; 18:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/23\">",
"      Guitart J, Woodley DT. Intertrigo: a practical approach. Compr Ther 1994; 20:402.",
"     </a>",
"    </li>",
"    <li>",
"     Friedmann, PS, Wilkinson, M. Occupational dermatoses. In: Dermatology, Bolognia, JL, Jorizzo, JL, Rapini, RP, et al (Eds), Mosby, London 2003. p.251.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/25\">",
"      Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591.",
"     </a>",
"    </li>",
"    <li>",
"     Kauffman, CL, Hamet, VH, Tahan, SR, et al. Fungal infections. In: Textbook of Dermatopathology, Barnhill, RL (Ed), McGraw-Hill, New York 2004. p. 479.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/27\">",
"      Chadbourne EB, Zhang S, Gordon MJ, et al. Clinical outcomes in reduction mammaplasty: a systematic review and meta-analysis of published studies. Mayo Clin Proc 2001; 76:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/28\">",
"      Runeman B. Skin interaction with absorbent hygiene products. Clin Dermatol 2008; 26:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/29\">",
"      Gray M. Optimal management of incontinence-associated dermatitis in the elderly. Am J Clin Dermatol 2010; 11:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/30\">",
"      Farage MA, Miller KW, Berardesca E, Maibach HI. Incontinence in the aged: contact dermatitis and other cutaneous consequences. Contact Dermatitis 2007; 57:211.",
"     </a>",
"    </li>",
"    <li>",
"     Phillips, RM, Rosen T. Topical antifungal agents. In: Comprehensive Dermatologic Drug Therapy, Wolverton SE (Ed), W.B Saunders, Philadelphia 2001. p.497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/32\">",
"      McClellan KJ, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs 1999; 58:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/33\">",
"      Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)--a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/34\">",
"      Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs 2009; 69:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/35\">",
"      Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg 2008; 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/36\">",
"      Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 2004; 43 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/37\">",
"      Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. Clin Ther 1985; 8:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/38\">",
"      Gupta AK, Bluhm R. Ciclopirox shampoo for treating seborrheic dermatitis. Skin Therapy Lett 2004; 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/39\">",
"      Sundaram SV, Srinivas CR, Thirumurthy M. Candidal intertrigo: treatment with filter paper soaked in Castellani's paint. Indian J Dermatol Venereol Leprol 2006; 72:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/40\">",
"      Leyden JJ. Corn starch, Candida albicans, and diaper rash. Pediatr Dermatol 1984; 1:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/41\">",
"      Cramer DW, Liberman RF, Titus-Ernstoff L, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999; 81:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/42\">",
"      Railan D, Wilson JK, Feldman SR, Fleischer AB. Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug's potency. Dermatol Online J 2002; 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/43\">",
"      Burnett BP, Mitchell CM. Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole. Cutis 2008; 82:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/44\">",
"      Stengel F, Robles-Soto M, Galimberti R, Suchil P. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. Int J Dermatol 1994; 33:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/45\">",
"      Nozickova M, Koudelkova V, Kulikova Z, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol 1998; 37:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/46\">",
"      Coldiron BM, Manders SM. Persistent Candida intertrigo treated with fluconazole. Arch Dermatol 1991; 127:165.",
"     </a>",
"    </li>",
"    <li>",
"     Gupta, AK. Systemic antifungal agents. In: Comprehensive Dermatologic Drug Therapy, Wolverton SE (Ed), W.B Saunders, Philadelphia 2001. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/48\">",
"      Pi&eacute;rard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/49\">",
"      Daning L, Dinguo Z, Wenwei S, Peihong J. Extensive skin candidosis in an adult: effective treatment with itraconazole. Mycoses 1998; 41:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/50\">",
"      Del Rosso JQ, Zellis S, Gupta AK. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections. J Am Osteopath Assoc 1998; 98:497.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.737.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/52\">",
"      Roberts, DT, Rishardson, MD, Dwyer, PK, et al. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 2(Suppl 1):39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/53\">",
"      Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/54\">",
"      Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/55\">",
"      Katz HI, Gupta AK. Oral antifungal drug interactions: a mechanistic approach to understanding their cause. Dermatol Clin 2003; 21:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30648/abstract/56\">",
"      Chapman MS, Brown JM, Linowski GJ. 0.1% tacrolimus ointment for the treatment of intertrigo. Arch Dermatol 2005; 141:787.",
"     </a>",
"    </li>",
"    <li>",
"     Habif, T. Clinical Dermatology, 4th ed. Mosby, Philadelphia 2004. p. 447.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4026 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-FFAD13B8AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30648=[""].join("\n");
var outline_f29_59_30648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Topical antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drying agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oral antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4026|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/34/30246\" title=\"picture 1\">",
"      Candidal intertrigo groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/15/18675\" title=\"picture 2\">",
"      Severe axillary intertrigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/44/18114\" title=\"picture 3\">",
"      Inframammary Candida intertrigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/7/24691\" title=\"picture 4\">",
"      Finger web intertrigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/43/28338\" title=\"picture 5\">",
"      Candidal intertrigo neck folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/16/257\" title=\"picture 6\">",
"      Abd and inguinal intertrigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/53/13136\" title=\"picture 7A\">",
"      Candidal diaper dermatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/53/4945\" title=\"picture 7B\">",
"      Candidal diaper dermatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/37/28242\" title=\"picture 8\">",
"      Hyphae candida albicans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/12/41167\" title=\"picture 9\">",
"      Candida albicans culture plate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/36/43587\" title=\"picture 10\">",
"      Intertriginous erythrasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4026|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/3/19517\" title=\"table 1\">",
"      Topical antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=related_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=related_link\">",
"      Glucagonoma and the glucagonoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_59_30649="Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children";
var content_f29_59_30649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30649/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30649/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30649/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/59/30649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemolytic-uremic syndrome (HUS) is defined by the simultaneous occurrence of the clinical triad:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Acute renal injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HUS is one of the main causes of acute renal injury in children. This disorder is divided by whether or not there is an association with bacteria that produce a Shiga toxin and clinical presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shiga toxin associated HUS &ndash; Shiga toxin (Stx) associated HUS is the most common form of HUS in children accounting for 90 percent of all cases. It usually occurs after a prodromal episode of diarrhea that is frequently bloody. In the majority of cases, Stx HUS is associated with strains of Escherichia coli that produce a Shiga toxin [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. This form is also referred to as typical, classical, or diarrhea-associated HUS, D+ HUS, or Shiga toxin-associated HUS.",
"     </li>",
"     <li>",
"      Non-Shiga toxin associated HUS &ndash; Non-Shiga toxin (NStx) associated HUS is a heterogeneous group of disorders distinguished clinically by the absence of diarrhea or Shiga toxin-producing E. coli infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. This disorder is also referred to as atypical, nondiarrhea-associated HUS, D- HUS, or sporadic HUS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of Stx HUS is presented in this topic review. The clinical manifestations and diagnosis of this disease are presented separately. The clinical manifestations, diagnosis, and treatment of NStx HUS also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link\">",
"     \"Atypical hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that Shiga toxin (Stx) hemolytic-uremic syndrome (HUS) is strongly associated with certain strains of enterohemorrhagic Escherichia coli (EHEC), which produce a Shiga-toxin such as type O157:H7, prevention of Stx HUS rests in part upon measures aimed at reducing the risk of EHEC infection. These preventive measures are discussed in detail elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=see_link&amp;anchor=H4451407#H4451407\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a patient is infected with EHEC, attempts to prevent progression from the bloody diarrheal phase (acute infectious phase) to the postdiarrheal phase of HUS have been largely unsuccessful (eg, antimotility drugs and antibiotics).",
"   </p>",
"   <p>",
"    Increased volume expansion with intravenous isotonic saline during the diarrheal phase has been reported to attenuate but not prevent renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. More vigorous fluid repletion during the diarrheal phase of the illness appeared to be associated with the development of less severe renal involvement",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114317253\">",
"    <span class=\"h2\">",
"     Failed preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics and antimotility drugs (such as anticholinergic agents and narcotics) do",
"    <strong>",
"     not",
"    </strong>",
"    reduce the progression to HUS due to EHEC infections, but in fact appear to increase the risk of subsequent development of HUS, and should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with confirmed or suspected EHEC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotics &ndash; In patients with EHEC, both retrospective and prospective observational studies report an increased risk of HUS with the administration of antibiotics during the bloody diarrheal phase. These studies also show that antibiotics do not decrease the duration of gastrointestinal symptoms. A review of these data is presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Treatment'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast to EHEC infections, antimicrobial therapy does not appear to increase the risk of Shigella dysenteriae type 1 associated HUS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Hemolytic-uremic syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antimotility drugs &ndash; In one retrospective review of 278 children with HUS, the use of antimotility drugs (anticholinergic agents and narcotics) was associated with an increased risk of subsequent development of HUS (OR 2.9, 95% CI 1.2-7.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/11\">",
"       11",
"      </a>",
"      ]. In another retrospective study of 91 patients, antimotility drugs (anticholinergic agents and narcotics) increased the risk of central nervous system dysfunction (OR 8.5, 95% CI 1.7-42.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/12\">",
"       12",
"      </a>",
"      ]. There was no difference in the duration of diarrhea between patients who received antimotility drugs and those who did not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of hemolytic-uremic syndrome (HUS) has improved in part because of the early institution of supportive therapy and improvements in intensive care and renal replacement therapy. Appropriate care should be given for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Fluid and electrolyte disturbances",
"     </li>",
"     <li>",
"      Acute renal failure",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Neurologic dysfunction",
"     </li>",
"     <li>",
"      Other organ involvement including colon, heart, pancreas, and lung",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HUS can become profoundly and rapidly anemic. Based upon clinical experience, packed red blood cells (RBC) should be transfused when the hemoglobin (Hgb) level is &lt;6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or hematocrit &lt;18 percent to avoid cardiovascular and pulmonary compromise. About 80 percent of children with Shiga toxin (Stx) HUS require PRBC transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link\">",
"     \"Indications for red blood cell transfusion in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A post-transfusion goal of an Hgb level between 8 to 9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is recommended to prevent cardiac and pulmonary complications resulting from high output cardiac failure. The goal is",
"    <strong>",
"     not",
"    </strong>",
"    to restore the Hgb level to normal because the increased volume may cause heart failure, pulmonary edema, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the concerns of hypervolemia, clinically indicated transfusions should be given slowly and cautiously with frequent monitoring of the patient's vital signs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/7\">",
"     7",
"    </a>",
"    ]. Transfusions should be stopped if the vital signs suggest cardiopulmonary vascular overload (eg, hypertension, tachycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tachypnea). Blood products should be volume-reduced and preferably depleted of leukocytes to avoid alloimmunization (thus reducing the risk of graft rejection in patients who may subsequently require renal transplantation). If the patient is undergoing hemodialysis, transfusions should be given during dialysis to minimize the risks of hypervolemia and hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H5#H5\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Leukoreduced red cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients do not require iron therapy, as iron from hemolyzed blood is available for erythropoiesis. In addition, there is no indication for the use of erythropoietin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet transfusion is reserved for patients with HUS who have significant clinical bleeding or if an invasive procedure is required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/7\">",
"     7",
"    </a>",
"    ]. This recommendation is based upon unsubstantiated concerns that consumption of infused platelets would contribute to new or expanding thrombi as reported in adults with thrombotic thrombocytopenic purpura [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Platelet transfusions are uncommon, as clinical significant bleeding is infrequent because the platelet count rarely falls below",
"    <span class=\"nowrap\">",
"     10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    In one retrospective study, there were no bleeding complications in 73 patients who required an invasive procedure (ie, peritoneal dialysis catheter or central venous catheter placement) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/17\">",
"     17",
"    </a>",
"    ]. In this cohort, the mean platelet counts were",
"    <span class=\"nowrap\">",
"     37,600/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in patients who received platelet transfusions and",
"    <span class=\"nowrap\">",
"     64,800/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in those not receiving transfusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fluid and electrolyte management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluid status of the patient with HUS must be carefully assessed to guide fluid management since competing processes can lead to either decreased or increased intravascular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/7\">",
"     7",
"    </a>",
"    ]. Decreased volume may result from vomiting, decreased oral intake, or diarrhea, while increased intravascular volume may arise from oliguria or anuria. In some cases, fluid expansion may be indicated to counteract renal hypoperfusion in volume-depleted patients. In contrast, fluid restriction may be needed in patients with increased intravascular volume due to",
"    <span class=\"nowrap\">",
"     oliguria/anuria.",
"    </span>",
"    Initial weight gain may not be an accurate marker for intravascular volume because hypoalbuminemia and capillary leakage may cause an edematous state, resulting in an increased total body water volume but a decreased intravascular volume.",
"   </p>",
"   <p>",
"    Fluid management is based upon the intravascular fluid status of the patient and renal function. Patients with decreased intravascular volume are repleted to a euvolemic state, whereas those with increased intravascular volume and diminished urine output are fluid restricted. Patients with increased intravascular may require dialysis treatment to remove fluid, especially if there is cardiac and pulmonary compromise. Once the patient is in a euvolemic state, administration of fluids should be given as insensible losses plus urine output until renal function returns to normal.",
"   </p>",
"   <p>",
"    Frequent monitoring of fluid balance, weight, and vital signs is imperative. At the first sign of hypertension or cardiopulmonary overload, fluids should be restricted. Diuretics rarely avert anuria but a trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    (2 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) may be attempted to induce a diuresis, particularly in patients with cardiopulmonary overload. Diuretics should not be continued in the patient who fails to respond. Dialysis therapy is required if fluid restriction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diuretic therapy fail to improve the compromised cardiorespiratory status of the patient in a timely manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link\">",
"     \"Prevention and management of acute kidney injury (acute renal failure) in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Dialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrolyte disturbances are common usually due to acute renal insufficiency or failure. They include hyperkalemia, hyperphosphatemia, and metabolic acidosis. Management of these disorders is the same as in patients with other causes of acute renal failure and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link&amp;anchor=H265511466#H265511466\">",
"     \"Prevention and management of acute kidney injury (acute renal failure) in children\", section on 'Electrolyte management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HUS who develop renal insufficiency or renal failure, nephrotoxic medications should be stopped. The dosing of drugs that are excreted by the kidney also must be readjusted for renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link&amp;anchor=H265511480#H265511480\">",
"     \"Prevention and management of acute kidney injury (acute renal failure) in children\", section on 'Drug management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that early dialysis affects clinical outcome. As a result, the indications for dialysis in children with HUS are similar to those in children with other forms of acute renal failure. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Signs and symptoms of uremia",
"     </li>",
"     <li>",
"      Azotemia defined as BUN &ge;80 to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (29 to 36",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Severe fluid overload (eg, cardiopulmonary compromise",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension) that is refractory to medical therapy",
"     </li>",
"     <li>",
"      Severe electrolyte abnormalities (eg, hyperkalemia and acidosis) that are refractory to medical therapy",
"     </li>",
"     <li>",
"      Need for nutritional support in a child with oliguria or anuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=see_link&amp;anchor=H4746395#H4746395\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\", section on 'Indications for and timing of RRT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of renal replacement modalities varies among pediatric nephrologists and medical centers. However, if there is a severe abdominal complication requiring surgical intervention, peritoneal dialysis is contraindicated. Earlier studies had preferentially recommended peritoneal dialysis because it more effectively removed the procoagulant, plasminogen-activator inhibitor type 1, which was thought to play a role in the pathogenesis of HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/18\">",
"     18",
"    </a>",
"    ]. However, there is no evidence of increased benefit of peritoneal dialysis compared to hemodialysis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Tissue-type plasminogen activator'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HUS, hypertension is caused by overexpansion of intravascular volume",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia-induced activation of the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/19\">",
"     19",
"    </a>",
"    ]. Management is directed toward correcting the fluid status and the use of antihypertensive agents. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Fluid'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Antihypertensive drugs used in patients with HUS include calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors (",
"    <a class=\"graphic graphic_table graphicRef71466 \" href=\"UTD.htm?13/30/13807\">",
"     table 1",
"    </a>",
"    ). There is, however, some concern that ACE inhibitors in the acute treatment of children with HUS may exacerbate renal injury by diminishing renal perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, there are proponents for the use of ACE inhibitors for its potential renoprotective effect in children with long-term sequelae of HUS (eg, proteinuria, renal insufficiency, and hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the use of calcium channel blockers (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"     nifedipine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     nicardipine",
"    </a>",
"    ) as the initial choice of antihypertensive agents because of the concern of reduced renal perfusion with ACE inhibitors. After the acute phase of HUS, we suggest that antihypertensive therapy is changed to ACE inhibitors in patients who appear to have long-term renal sequelae. Long-term ACE inhibitor therapy may be beneficial as it reduces protein excretion, which may retard chronic renal disease progression as well as lower blood pressure in hypertensive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neurologic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications of the central nervous system (CNS), such as seizures and strokes, are predictors of poor outcome. In any patient with HUS who presents with serious neurologic dysfunction (eg, seizure and coma), radiological imaging should be performed to assess for CNS infarction. Seizures also may be secondary to severe hypertension.",
"   </p>",
"   <p>",
"    Seizures are treated with parenteral antiepileptic agents. These include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and fos-phenytoin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in the related disorder thrombotic thrombocytopenic purpura (TTP) that has severe neurologic dysfunction have shown plasma exchange improved clinical outcome. Although unproven in patients with HUS, plasma exchange has been used in patients with severe CNS involvement (eg, stroke). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Plasma infusion and plasma exchange'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Plasma exchange procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not as common as renal and neurologic complications, patients may develop severe gastrointestinal complications, cardiac dysfunction, and pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/13,22\">",
"     13,22",
"    </a>",
"    ]. In addition, respiratory complications secondary to increased intravascular volume may occur. Management for these potential complications includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal complications &ndash; Severe colitis may progress to necrosis and in some cases intestinal perforation. Management includes serial abdominal examinations, guaiac testing of the stool, and the use of parenteral nutrition. Surgical intervention may be required.",
"     </li>",
"     <li>",
"      Cardiac dysfunction &ndash; Cardiac dysfunction can be a result of cardiac ischemia and fluid overload. Pericarditis may be associated with uremia. Appropriate therapy should be directed to the underlying pathology and may include inotropic agents, fluid restriction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dialysis.",
"     </li>",
"     <li>",
"      Pancreatitis &ndash; Clinically significant pancreatitis can occur resulting in insulin deficiency. Insulin therapy may be required for hyperglycemia.",
"     </li>",
"     <li>",
"      Pulmonary complications &ndash; Pulmonary edema and effusions may result from intravascular fluid overload. Management may include fluid restriction, diuretics, dialysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventilatory support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple modalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    agents have been utilized that are directed against the underlying or presumed pathogenic mechanisms of Shiga toxin (Stx) hemolytic-uremic syndrome (HUS). These include antithrombotic agents, plasma exchange",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasma infusion, tissue-type plasminogen activator, and oral Shiga toxin-binding agent.",
"   </p>",
"   <p>",
"    Although none of these agents have been shown to be efficacious, there may be a role for plasma",
"    <span class=\"nowrap\">",
"     exchange/plasmapheresis,",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    (a monoclonal antibody that blocks complement activity by cleavage of C5), in patients with CNS involvement. The remaining agents are",
"    <strong>",
"     not",
"    </strong>",
"    recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Plasma infusion and plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of plasma infusion (to supply a missing anticoagulant factor) or plasma exchange (to supply a missing anticoagulant factor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    remove procoagulant factor) has been successful in many adults with thrombotic thrombocytopenic purpura (TTP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations provided the rationale to evaluate these modalities in children with Stx HUS. The benefit of plasma infusion of fresh frozen plasma (FFP) was evaluated by a French prospective multicenter trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/23\">",
"     23",
"    </a>",
"    ]. All patients received supportive care, 39 patients also received FFP (10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    daily for seven days) compared to 40 control patients who only received supportive treatment. The plasma creatinine concentration and urinary protein excretion were higher at six-month follow-up in the control group, but these differences were not found at 12 months follow-up. Late renal biopsy revealed cortical necrosis in seven of the control patients but none of the plasma-treated patients. A smaller controlled trial in Italy showed",
"    <strong>",
"     no",
"    </strong>",
"    benefit with FFP in terms of either the plasma creatinine concentration or renal histology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized controlled studies that evaluate the efficacy of plasma exchange in children with Stx HUS. There was one report with a small number of patients that suggested plasma exchange shortened the duration of acute renal failure and lead to better long-term renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/25\">",
"     25",
"    </a>",
"    ]. In a meta-analysis that evaluated plasma exchange from four observational studies, there was",
"    <strong>",
"     no",
"    </strong>",
"    clinical benefit seen with plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the small number of studies that are observational in their design and the variability of the clinical spectrum of disease hamper the analysis.",
"   </p>",
"   <p>",
"    Plasma exchange can be used in children with Stx HUS and severe CNS involvement (eg, stroke) based upon reported benefits with plasma exchange in adults with TTP and severe neurologic dysfunction, although there is no evidence that it is beneficial in the treatment of Stx HUS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Plasma exchange procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The volume of exchange is 40 to 60",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    and FFP is generally used as the replacement fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4043038\">",
"    <span class=\"h2\">",
"     Eculizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    , a monoclonal antibody to complement factor C5 that blocks complement activation, has been used in the treatment of patients with atypical HUS due to complement dysregulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link&amp;anchor=H8#H8\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Complement dysregulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    may also be beneficial in patients with Stx HUS and CNS involvement. In a case report of three children with Stx HUS and significant CNS findings, the neurologic status of all three patients improved within 24 hours of eculizumab administration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/27\">",
"     27",
"    </a>",
"    ]. Clinical improvement was also associated with rapid normalization of platelet counts. All three patients were subsequently discharged home with normal neurologic status and fully restored renal function. The authors suggest that recovery was due to eculizumab therapy because most cases with this level of CNS involvement do not show this degree of resolution within such a short time period (ie, 24 hours).",
"   </p>",
"   <p>",
"    Additional support for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    was provided by a study that demonstrated the presence of microparticles with surface-bound C3 and C9 derived from platelets and monocytes in plasma samples from 13 patients with Stx HUS during the acute phase of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/28\">",
"     28",
"    </a>",
"    ]. Levels of microparticles and",
"    <span class=\"nowrap\">",
"     C3/C9",
"    </span>",
"    binding decreased during the recovery phase and approached the levels seen in samples from control patients. Additional experiments demonstrated that in vitro incubation of donor whole blood (not infected with EHEC) with different forms of Shiga toxins or lipopolysaccharide from E. coli 0157 induced a significant increase in platelet-monocyte and platelet-neutrophil complexes and microparticles with surface-bound C3. These results provide a rationale for the use of eculizumab with evidence that complement activation contributes to the inflammatory and prothrombotic mechanisms that are involved in the pathogenesis of this disease.",
"   </p>",
"   <p>",
"    Although these data are limited and preliminary, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    be given to patients with Stx HUS and CNS involvement because these patients are at significant risk for death and long-term morbidity. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Prognosis'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    is based on a regimen used in a clinical trial for eculizumab treatment in patients with atypical (NStx) HUS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link&amp;anchor=H15#H15\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is the initial dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    to treat Stx HUS, which is dependent on patient&rsquo;s body weight:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      5 to &lt;10 kg &ndash; 300 mg",
"     </li>",
"     <li>",
"      10 to &lt;40 kg &ndash; 600 mg",
"     </li>",
"     <li>",
"      &ge;40 kg &ndash; 900 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision for additional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    is dependent on the clinical status of the patient. If plasmapheresis therapy is also being performed, a repeat dose is given after each plasmapheresis session.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antithrombotic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of antithrombotic agents in HUS was based upon the histologic evidence of thrombus formation. It is important to remember, however, this disorder is primarily characterized by platelet rather than fibrin consumption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two prospective controlled trials have compared combinations of antithrombotic agents (eg, either urokinase and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/43/11958?source=see_link\">",
"     dipyridamole",
"    </a>",
"    and heparin) with supportive care or with supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The duration of renal failure, hemolysis, and thrombocytopenia, and the long-term outcome were all similar in both control and treated groups. Furthermore, hemorrhagic complications were more common in the treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend antithrombotic agents in patients with Stx HUS because there is no evidence of clinical benefit and there is an increased risk of hemorrhagic complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oral Shiga toxin-binding agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a placebo-controlled randomized study of 145 children diagnosed with HUS, Synsorb-Pk, an oral agent that binds Shiga toxin, did not improve clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/31\">",
"     31",
"    </a>",
"    ]. The incidence of death or serious extrarenal events was the same in the treated and placebo control groups (18 and 20 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tissue-type plasminogen activator",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that plasminogen activator inhibitor type 1 (PAI-1) may be a circulating inhibitor of fibrinolysis in the HUS. In one report, for example, normalization of plasma PAI-1 levels correlated with improvement in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/18\">",
"     18",
"    </a>",
"    ]. One case report described a successful response to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematologic manifestations of Shiga toxin (Stx) hemolytic-uremic syndrome (HUS) completely resolve usually within one to two weeks. The prognosis for recovery of renal function is generally favorable, with resolution beginning after hematologic improvement. The mortality rate is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/33-35\">",
"     33-35",
"    </a>",
"    ] but another 5 percent of patients have significant sequelae (eg, stroke or end-stage renal disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/33\">",
"     33",
"    </a>",
"    ]. Outcome results generally are from data of patients with 0157:H7 associated HUS. A similar favorable outcome was also observed in children who were affected during the large German HUS-outbreak in 2011 due to E. coli O104:H4 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/36\">",
"     36",
"    </a>",
"    ]. In these 90 affected children, four had renal impairment and four had neurologic sequelae (although still improving) at four months follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182809768\">",
"    <span class=\"h2\">",
"     Acute mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective review of 17 children who died from HUS compared to nonfatal cases of HUS, fifteen died during the acute phase of HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/37\">",
"     37",
"    </a>",
"    ]. Eight patients died of disease involving the CNS. Other causes of death included hyperkalemia, heart failure, and pulmonary hemorrhage. Patients who presented with oligoanuria, dehydration, an elevated WBC &gt;20,000 per mm",
"    <sup>",
"     3",
"    </sup>",
"    , and a hematocrit &gt;23 percent were at increased risk for death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have long-term complications from HUS often have one or more of the following risk factors during the acute phase of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/33-35,38\">",
"     33-35,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A white blood cell count &gt;20,000 per mm",
"      <sup>",
"       3",
"      </sup>",
"      at presentation. The leukocytosis in part reflects neutrophil activation resulting from monocytes release of the neutrophil chemoattractant interleukin-8; these neutrophils may then contribute to tissue damage [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initial",
"      <span class=\"nowrap\">",
"       oliguria/anuria",
"      </span>",
"      that is persistent (&gt;5 days of anuria and &gt;10 days of oliguria) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal histology showing a glomerular microangiopathy affecting &gt;50 percent of glomeruli, arterial microangiopathy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cortical necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182809569\">",
"    <span class=\"h3\">",
"     Renal outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerular filtration rate (GFR) returns to normal in most children with Stx HUS. However, renal blood flow may be persistently reduced by 10 to 20 percent, suggesting there may be some permanent subclinical nephron loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Permanent and serious renal sequelae are reported in 5 to 25 percent of children with Stx HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/26,34,35,38,42\">",
"     26,34,35,38,42",
"    </a>",
"    ]. Long-term follow-up often reveals evidence of irreversible injury during the acute phase of the disease. These include an increased incidence of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Mild proteinuria (usually less than 1000 mg per day)",
"     </li>",
"     <li>",
"      Subclinical decline in GFR with plasma creatinine concentration remaining in the normal range",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two reports with a mean follow-up of 8 to 10 years have suggested these changes occur in up to one-third of children with prolonged initial disease defined as anuria &gt;8 days or oliguria &gt;15 days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In comparison, the GFR is reduced in less than 10 percent of cases with less severe primary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study of 29 patients with much longer follow-up (mean 18 years) suggested late renal dysfunction may be more common than previously reported in childhood Stx HUS, particularly in those who required dialysis during the acute episode [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/43\">",
"     43",
"    </a>",
"    ]. Only 10 of 29 patients had no renal abnormality, 12 had residual proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension, three had chronic renal failure, and four had progressed to end-stage renal disease. The findings at initial renal biopsy were somewhat predictive of long-term outcome. The prognosis was generally good in those with glomerular thrombi involving &lt;50 percent of glomeruli; in contrast, almost all children with vascular thrombi and patchy cortical necrosis had persistent or progressive disease.",
"   </p>",
"   <p>",
"    Furthermore, a normal GFR at late follow-up does not necessarily imply complete renal recovery. Some patients with a normal serum creatinine have a persistent reduction in renal blood flow and a lower-than-normal maximum GFR after a protein load [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/1,41\">",
"     1,41",
"    </a>",
"    ]. These findings suggest permanent nephron loss, with compensatory hyperfiltration in the surviving nephrons, which maintains the total filtration rate. Sequential renal biopsies may show glomerular scarring, which could reflect secondary hemodynamically mediated glomerular injury resulting from the initial nephron loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Recurrence after renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with Stx HUS who progress to end-stage renal failure and undergo renal transplantation, recurrence of HUS in the transplanted kidney is rare (zero to 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/1,44-49\">",
"     1,44-49",
"    </a>",
"    ]. In one review of 118 children, there was only one case of recurrence with allograft loss (0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, allograft survival in patients with Stx HUS is similar to survival in those with other causes of renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30649/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the diagnosis of recurrence of HUS after renal transplantation may be difficult. Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and other calcineurin inhibitors have no detrimental effect on recurrence, these immunosuppressive agents may cause a nephropathy that has many features in common with HUS. In addition, it may be difficult to distinguish recurrence of HUS from severe acute vascular or chronic rejection on a renal biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, yearly evaluation of patients with Shiga toxin (Stx) hemolytic-uremic syndrome (HUS) is recommended to monitor for signs of hypertension, proteinuria, and renal insufficiency. Thus, each visit should include blood pressure measurement and laboratory evaluation of renal function including urinalysis and serum creatinine concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prevention of HUS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevention of Shiga toxin (Stx) hemolytic-uremic syndrome (HUS) is dependent on measures that decrease the risk of infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=see_link&amp;anchor=H4451407#H4451407\">",
"       \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no known effective therapy to prevent progression from the bloody diarrheal phase (acute infectious phase) to the postdiarrheal phase of HUS.",
"     </li>",
"     <li>",
"      In patients with confirmed or suspected infections due to enterohemorrhagic Escherichia coli, we recommend antibiotics and antimotility agents",
"      <strong>",
"       not",
"      </strong>",
"      be given (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management of acute phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for Stx HUS is supportive and includes the following (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Symptomatic therapy'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with HUS can become profoundly and rapidly anemic and require red blood cell transfusions. In our clinical experience, we transfuse when the hemoglobin level falls below 6",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest platelet transfusion only if there is active bleeding or prior to a required invasive procedure in patients with platelet counts less than",
"      <span class=\"nowrap\">",
"       30,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For each patient, the fluid status is assessed and management is directed toward returning the patient to a euvolemic state. Fluids are then administered as insensible plus urine output until renal function returns to normal. Frequent monitoring of fluid balance, weight, and vital signs are required to detect early signs of fluid overload. If this occurs, prompt fluid restriction is begun. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial assessment and monitoring are required to detect hyperkalemia, hyperphosphatemia, and metabolic acidosis. Management of these disorders is the same as in patients with other causes of acute renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link&amp;anchor=H265511466#H265511466\">",
"       \"Prevention and management of acute kidney injury (acute renal failure) in children\", section on 'Electrolyte management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis therapy is initiated as indicated for acute renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link&amp;anchor=H265511487#H265511487\">",
"       \"Prevention and management of acute kidney injury (acute renal failure) in children\", section on 'Renal replacement therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=see_link\">",
"       \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is managed by fluid restriction, antihypertensive agents, and dialysis if needed. We suggest the use of calcium channel blockers (such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"       nifedipine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"       nicardipine",
"      </a>",
"      ) as the initial choice of antihypertensive agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parenteral antiepileptic agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and fos-phenytoin) are used in the management of seizures in patients with HUS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"       \"Management of status epilepticus in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Based upon data demonstrating successful treatment outcome in adults with thrombotic thrombocytopenic purpura, we suggest plasma exchange be used in patients with significant neurologic symptoms, such as seizures or strokes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with neurologic involvement, we suggest administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      , a monoclonal antibody to complement factor C5 that blocks complement activation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4043038\">",
"       'Eculizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       not",
"      </strong>",
"      recommend the use of antithrombotic agents or oral Shiga toxin-binding agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognosis and follow-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, the short-term prognosis is favorable with mortality rates below 5 percent. However, the risk of renal failure 20 years after recovery is not negligible and long-term follow-up is recommended. In patients who require renal transplantation, recurrence of HUS is rare. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Yearly evaluations of patients with HUS include blood pressure measurement, urinalysis, and serum creatinine. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the acute phase of HUS, we suggest that ACE inhibitors are given in patients who appear to have renal sequelae (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/1\">",
"      Repetto HA. Epidemic hemolytic-uremic syndrome in children. Kidney Int 1997; 52:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/2\">",
"      Yukioka H, Kurita S. Escherichia coli O157 infection disaster in Japan, 1996. Eur J Emerg Med 1997; 4:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/3\">",
"      Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/4\">",
"      Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/5\">",
"      Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004; 43:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/6\">",
"      Neuhaus TJ, Calonder S, Leumann EP. Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child 1997; 76:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/7\">",
"      Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/8\">",
"      Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115:e673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/9\">",
"      Trachtman H. Does parenteral volume expansion improve outcomes in children infected with Escherichia coli O157:H7? Nat Clin Pract Nephrol 2005; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/10\">",
"      Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/11\">",
"      Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100:E12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/12\">",
"      Cimolai N, Morrison BJ, Carter JE. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics 1992; 90:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/13\">",
"      Brandt JR, Fouser LS, Watkins SL, et al. Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994; 125:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/14\">",
"      Kaplan BS, Thomson PD, de Chadar&eacute;vian JP. The hemolytic uremic syndrome. Pediatr Clin North Am 1976; 23:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/15\">",
"      Harkness DR, Byrnes JJ, Lian EC, et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981; 246:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/16\">",
"      Lind SE. Thrombocytopenic purpura and platelet transfusion. Ann Intern Med 1987; 106:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/17\">",
"      Weil BR, Andreoli SP, Billmire DF. Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome. Pediatr Nephrol 2010; 25:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/18\">",
"      Bergstein JM, Riley M, Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 1992; 327:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/19\">",
"      Powell HR, Rotenberg E, Williams AL, McCredie DA. Plasma renin activity in acute poststreptococcal glomerulonephritis and the haemolytic-uraemic syndrome. Arch Dis Child 1974; 49:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/20\">",
"      Van Dyck M, Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 2004; 19:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/21\">",
"      Caletti MG, Lejarraga H, Kelmansky D, Missoni M. Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome. Pediatr Nephrol 2004; 19:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/22\">",
"      Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994; 125:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/23\">",
"      Loirat C, Sonsino E, Hinglais N, et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988; 2:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/24\">",
"      Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/25\">",
"      Slavicek J, Pureti�� Z, Novak M, et al. The role of plasma exchange in the treatment of severe forms of hemolytic-uremic syndrome in childhood. Artif Organs 1995; 19:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/26\">",
"      Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/27\">",
"      Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/28\">",
"      St&aring;hl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/29\">",
"      Loirat C, Beaufils F, Sonsino E, et al. [Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial]. Arch Fr Pediatr 1984; 41:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/30\">",
"      Van Damme-Lombaerts R, Proesmans W, Van Damme B, et al. Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. J Pediatr 1988; 113:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/31\">",
"      Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/32\">",
"      Kruez W, Linde R, Becker S, Seifried E. Successful treatment of haemolytic uraemic syndrome with recombinant tissue-type plasminogen activator. Lancet 1993; 341:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/33\">",
"      Siegler RL, Pavia AT, Christofferson RD, Milligan MK. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994; 94:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/34\">",
"      Siegler RL, Milligan MK, Burningham TH, et al. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr 1991; 118:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/35\">",
"      Fitzpatrick MM, Shah V, Trompeter RS, et al. Long term renal outcome of childhood haemolytic uraemic syndrome. BMJ 1991; 303:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/36\">",
"      Loos S, Ahlenstiel T, Kranz B, et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/37\">",
"      Oakes RS, Siegler RL, McReynolds MA, et al. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 2006; 117:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/38\">",
"      Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/39\">",
"      Fitzpatrick MM, Shah V, Trompeter RS, et al. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int 1992; 42:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/40\">",
"      Oakes RS, Kirkham JK, Kirkhamm JK, et al. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008; 23:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/41\">",
"      Georgaki-Angelaki HN, Steed DB, Chantler C, Haycock GB. Renal function following acute renal failure in childhood: a long term follow-up study. Kidney Int 1989; 35:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/42\">",
"      Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet 1998; 352:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/43\">",
"      Gagnadoux MF, Habib R, Gubler MC, et al. Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome. Clin Nephrol 1996; 46:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/44\">",
"      Eijgenraam FJ, Donckerwolcke RA, Monnens LA, et al. Renal transplantation in 20 children with hemolytic-uremic syndrome. Clin Nephrol 1990; 33:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/45\">",
"      Bassani CE, Ferraris J, Gianantonio CA, et al. Renal transplantation in patients with classical haemolytic-uraemic syndrome. Pediatr Nephrol 1991; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/46\">",
"      Gagnadoux MF, Habib R, Niaudet P, et al. Results of renal transplantation in childhood hemolytic-uremic syndrome. J Am Soc Nephrol 1996; 7:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/47\">",
"      Miller RB, Burke BA, Schmidt WJ, et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant 1997; 12:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/48\">",
"      M&uuml;ller T, Sikora P, Offner G, et al. Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center. Clin Nephrol 1998; 49:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30649/abstract/49\">",
"      Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18:1095.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6097 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30649=[""].join("\n");
var outline_f29_59_30649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114317253\">",
"      Failed preventive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMATIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fluid and electrolyte management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neurologic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other organ involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Plasma infusion and plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4043038\">",
"      Eculizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antithrombotic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oral Shiga toxin-binding agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tissue-type plasminogen activator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182809768\">",
"      Acute mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182809569\">",
"      - Renal outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Recurrence after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prevention of HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management of acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognosis and follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6097\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6097|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/30/13807\" title=\"table 1\">",
"      Antihypertensive drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=related_link\">",
"      Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=related_link\">",
"      Prevention and management of acute kidney injury (acute renal failure) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_59_30650="Noninvasive assessment of hepatic fibrosis";
var content_f29_59_30650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninvasive assessment of hepatic fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30650/contributors\">",
"     Michael P Curry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30650/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30650/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/59/30650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/59/30650/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/59/30650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic fibrosis occurs in response to chronic liver injury in almost all patients. Regardless of the cause, the response to liver injury includes collapse of hepatic lobules, formation of fibrous septae, and hepatocyte regeneration with nodular formation. Extracellular matrix (ECM) components accumulate in the liver as a result of imbalances in their production, deposition, and degradation. This diffuse process may ultimately progress to cirrhosis with its accompanying consequences of portal hypertension and impaired hepatic function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link\">",
"     \"Pathogenesis of hepatic fibrosis\"",
"    </a>",
"    .) Originally thought of as irreversible, hepatic fibrosis is now recognized as a dynamic process with the potential for significant resolution. New molecular insights into fibrogenesis and fibrosis regression offer potential targets for antifibrotic therapy and increase the need for noninvasive means to measure changes in fibrosis.",
"   </p>",
"   <p>",
"    Conventional biochemical and serological tests, when examined alone, are of little value for the assessment of fibrosis. As a result, histopathological examination of a liver biopsy specimen is currently the gold-standard for staging of liver disease. However, a liver biopsy has many limitations. Because it is invasive, it is usually not welcomed by patients. In addition, it can only sample a small portion of the liver and is thereby susceptible to sampling variation and inter- and intra-observer variability.",
"   </p>",
"   <p>",
"    These issues provided the rationale for the development of noninvasive means to estimate the amount of hepatic scar tissue to aid in treatment decisions and monitor either progression or resolution of fibrosis. A number of tools are currently available or in development for the noninvasive assessment of hepatic fibrosis, which will be reviewed here. The histologic assessment of hepatic fibrosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=see_link\">",
"     \"Histologic scoring systems for chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CROSS-SECTIONAL IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT, MRI, and ultrasound scans can reliably demonstrate features of advanced liver disease such nodularity and signs of portal hypertension. However, the resolution of hepatic parenchyma with any of the available modalities is insufficient to determine the earlier stages of fibrosis. The main role for radiological imaging is the confirmation of cirrhosis in patients with a high clinical suspicion of advanced chronic liver disease. In addition, imaging tests can provide complementary information in patients in whom liver biopsy results are indeterminate or at variance with the clinical impression.",
"   </p>",
"   <p>",
"    Several modifications to standard ultrasonography have been proposed to increase accuracy for diagnosis of cirrhosis and portal hypertension. Sensitivity, specificity, and accuracy for identifying cirrhosis were 84, 100, and 94 percent, respectively, in one study that used the ratio of the transverse caudate lobe width with the transverse right lobe width [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/1\">",
"     1",
"    </a>",
"    ]. In other reports, up to 11 sonographic and Doppler measurements reported accuracy of cirrhosis detection of between 82 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. One study found that measurement of the splenic Doppler impedance ratio was an accurate predictor of cirrhosis yielding an area under the receiver operating curve (AUROC) of 0.92 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/4\">",
"     4",
"    </a>",
"    ]. However, most of these approaches have not been well validated, and their clinical utility may be influenced by variations in anatomy and inconsistent interobserver agreement.",
"   </p>",
"   <p>",
"    Diffusion weighted MRI measures the apparent diffusion coefficient of water, a parameter that depends upon tissue structure. Initial studies suggested that it compared favorably to other noninvasive measures for determining advanced fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIVER STIFFNESS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69601958\">",
"    <span class=\"h2\">",
"     Ultrasound-based transient elastography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A technique based upon elastography has emerged as a promising approach for staging hepatic fibrosis. Transient elastography rapidly and noninvasively measures the mean hepatic tissue stiffness. Using a probe (FibroScan), which includes an ultrasonic transducer, a vibration of low frequency (50 MHz) and amplitude is transmitted into the liver. The vibration wave induces an elastic shear wave that propagates through the organ. The velocity of this wave as it passes through the liver correlates directly with tissue stiffness. The harder or stiffer the tissue, the faster the shear wave propagates. Results are expressed in kilopascals (kPa) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FibroScan measures liver stiffness of a volume that is approximately a cylinder of 1 cm diameter and 5 cm long, which is 100 times greater in size than a standard liver biopsy, and thus may be more representative of the entire hepatic parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies have described test characteristics of ultrasound-based elastography. At least three meta-analyses have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The most recent (which included 50 studies) estimated test characteristics by reporting the AUROC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/11\">",
"     11",
"    </a>",
"    ]. The accuracy of a diagnostic test using this measure increases as the AUROC approaches the value 1.0.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean AUROC for diagnosis of significant fibrosis, severe fibrosis and cirrhosis were 0.84, 0.89, and 0.94, respectively.",
"     </li>",
"     <li>",
"      Estimates for diagnosis of significant fibrosis were influenced by the type of underlying liver disease and the cut off level for diagnosis of cirrhosis may be different for each disease. The most consistent findings were in patients with hepatitis C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An earlier meta-analysis of nine studies provided summary estimates as sensitivity and specificity, which are easier to interpret [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For cirrhosis, sensitivity was 87 percent (95% CI 84-90%) and specificity was 91 percent (95% CI 89-92%).",
"     </li>",
"     <li>",
"      For stages II-IV fibrosis, sensitivity was 70 percent (95% CI 67-73%) and specificity was 84 percent (95% CI 80-88%).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third meta-analysis focused on patients with hepatitis C who had undergone liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/12\">",
"     12",
"    </a>",
"    ]. The meta-analysis found that for significant fibrosis, the sensitivity and specificity were both 83 percent, and for cirrhosis were 98 and 84 percent, respectively.",
"   </p>",
"   <p>",
"    This technology fulfills many features desirable of noninvasive assessment of hepatic fibrosis. It is quick, inexpensive, reproducible, painless, and examines a large mass of liver tissue thereby reducing sampling error.",
"   </p>",
"   <p>",
"    Liver stiffness may also be associated with prognosis. In a study of patients coinfected with HIV and HCV, 239 patients were diagnosed with compensated cirrhosis based upon transient elastography [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/13\">",
"     13",
"    </a>",
"    ]. Cirrhosis was defined by a liver stiffness of &gt;14 kPa. During a median follow-up of 20 months, patients with liver stiffness values &ge;40 kPa were more likely to develop decompensation than those with values &lt;40 kPa (29 versus 8 percent). On multivariable analysis, liver stiffness was a predictor of decompensation during follow-up (for each kPa increase, the hazard ratio was 1.03, 95% CI 1.01-1.05). In addition, in a study of patients undergoing hepatectomy for hepatocellular carcinoma, a liver stiffness &gt;15.7 kPa was a risk factor for post operative liver failure (sensitivity 96 percent, specificity 69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the technique may be limited in patients with ascites, patients with elevated central venous pressure (such as heart failure), and those who are obese, since fluid and adipose tissue attenuate the elastic wave [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A probe has been developed (FibroScan XL probe) in an attempt to improve accuracy in obese patients. Studies suggest that it is able to accurately assess the degree of fibrosis but that it may not be superior to the standard M probe in obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 210 patients with chronic liver disease and a body mass index (BMI) of 28 or higher, elastography results using the FibroScan XL probe were compared with liver biopsy results [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/17\">",
"       17",
"      </a>",
"      ]. The degree of fibrosis estimated by FibroScan was within one stage of biopsy in 186 patients (88 percent), and was the same as that on biopsy in 123 (59 percent). In the majority of patients with discordant results (59 of 87; 68 percent), the FibroScan estimate of fibrosis stage was higher than that determined by liver biopsy.",
"     </li>",
"     <li>",
"      In a study with 286 patients with BMIs ranging from 16 to 51, there was no difference in the ability to diagnose fibrosis between the XL probe and the M probe, regardless of BMI [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/18\">",
"       18",
"      </a>",
"      ]. However, among the 58 patients with either no valid measurement or an unreliable measurement with the M probe, 33 (57 percent) had a reliable measurement with the XL probe, suggesting that it may be valuable to assess patients with an XL probe if measurements obtained with the M probe fail to provide an estimate of liver stiffness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hepatic inflammation can reduce accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. In one report, for example, results were not reliable in patients with acute viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/21\">",
"     21",
"    </a>",
"    ]. Similarly, in a study of patients with alcoholic hepatitis, postponing the examination until after the serum AST declined to less than 100",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    improved diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/23\">",
"     23",
"    </a>",
"    ]. Another study in patients with alcoholic cirrhosis found that accuracy could be improved by using nonstandard cutoff values (17 kPa for F3 fibrosis and 21.1 kPa for F4 fibrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors also influence liver stiffness values. In a study of 429 consecutive, apparently healthy volunteers, liver stiffness values were higher in men (5.81 versus 5.23), those with a body mass index &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (6.26 versus 5.33), and those with the metabolic syndrome (6.51 versus 5.33) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/20\">",
"     20",
"    </a>",
"    ]. One study found it overestimated liver fibrosis in patients with an elevated serum ALT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/26\">",
"     26",
"    </a>",
"    ]. Another study found that results varied depending upon the operator's experience with performing the examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/16\">",
"     16",
"    </a>",
"    ]. It is not clear if steatosis influences the accuracy of ultrasound-based elastography, with some studies showing it decreases the accuracy, whereas others have found no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69601973\">",
"    <span class=\"h2\">",
"     Magnetic resonance elastography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elastography can also be performed with MRI. The technique involves placing a probe to the back of the patient, which emits low frequency vibrations through the liver which can be measured by the MRI spin echo sequence. A meta-analysis that included five studies of MRI-elastography (MRE) found the following test characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Differentiating F0-F1 fibrosis from F2 to F4 fibrosis: Sensitivity 0.94, specificity 0.95",
"     </li>",
"     <li>",
"      Differentiating F0-F2 fibrosis from F3 to F4 fibrosis: Sensitivity 0.92, specificity 0.96",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRE has been compared with ultrasound-based elastography. In one report, MRE had similar test characteristics to ultrasound elastography [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/29\">",
"     29",
"    </a>",
"    ]. Another study found that MRE had a higher technical success rate and better diagnostic accuracy compared with ultrasound elastography [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/30\">",
"     30",
"    </a>",
"    ]. MRE also has the advantage of scanning the entire liver and thus does not depend upon an acoustic window. Both ultrasound and MR elastography have limitations in specific patient populations and the appropriate combination of these technologies awaits further studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69601980\">",
"    <span class=\"h2\">",
"     Other ultrasound-based techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acoustic radiation force impulse (ARFI) is another ultrasound-based approach for estimating liver stiffness. ARFI uses short-duraton, high intensity acoustic pulses to produce mechanical excitation in tissue. This results in localized tissue displacement and shear wave propagation. The velocity of these waves correlates with the degree of fibrosis (the shear wave velocity increases as the amount of fibrosis increases), though optimal cutoff values vary among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/31-43\">",
"     31-43",
"    </a>",
"    ]. In a representative study that included a training set of 88 patients, the sensitivity of ARFI for F2 fibrosis was 85 percent using a cutoff of 1.44",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"    and for F4 fibrosis was 92 percent using a cutoff of 1.9",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/42\">",
"     42",
"    </a>",
"    ]. The corresponding specificities were 76 and 87 percent, respectively.",
"   </p>",
"   <p>",
"    Real-time shear wave elastography (SWE) is a technique that is based on the same principles as transient elastography. SWE estimates the speed of a shear wave through the liver to measure liver stiffness. In a study that included 121 patients with chronic hepatitis C who were undergoing liver biopsy, using a cutoff of 7.1 kPa, the sensitivity of SWE for detecting &ge;F2 fibrosis was 90 percent, and the specificity was 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/44\">",
"     44",
"    </a>",
"    ]. Using a cutoff of 10.4 kPa, the sensitivity of SWE for detecting F4 fibrosis was 88 percent, and the specificity was 97 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SERUM BIO-MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of serologic markers have been evaluated in the hope that they would reflect the degree of fibrosis in the liver. Because hepatic fibrogenesis is a dynamic process, most of the tests are more suitable for determining the rate of fibrosis development and response to therapy rather than assessing stage of disease at one particular time point. As a result, it is likely that a panel of such assays will be required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/45\">",
"     45",
"    </a>",
"    ]. However, a systematic review of 14 studies of fibrosis panels in patients with hepatitis C concluded that cutoff-levels that gave clinically relevant predictive values for the",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of significant fibrosis were applicable to only 35 percent of patients and the fibrosis panels could not differentiate stages of fibrosis reliably [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed markers of hepatic fibrosis can be broadly divided into indirect and direct.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indirect markers reflect alterations in hepatic function but do not directly reflect extracellular matrix metabolism. Examples include the platelet count, coagulation studies, and liver aminotransferases.",
"     </li>",
"     <li>",
"      Direct markers of fibrosis reflect extracellular matrix metabolism turnover.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INDIRECT MARKERS OF FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of serum aminotransferase levels, coagulation parameters, and platelet counts have been used in clinical practice to determine the presence or absence of cirrhosis. Several studies have also evaluated the accuracy of combinations (or ratios) of these measures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. None has yet evolved as a standard for clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     AST/ALT ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio is approximately 0.8 in normal subjects. Some studies have suggested that a ratio greater than 1 suggests the presence of cirrhosis. However, results have been inconsistent and thus the clinical utility of this ratio for diagnosis of cirrhosis remains uncertain. The",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio has also been incorporated in predictive models in patients with nonalcoholic fatty liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     AST to platelet ratio index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AST to platelet ratio index (APRI) is calculated as follows:",
"   </p>",
"   <p>",
"    APRI = (AST",
"    <span class=\"nowrap\">",
"     elevation/platelet",
"    </span>",
"    count) x 100",
"   </p>",
"   <p>",
"    Where the AST elevation is the",
"    <span class=\"nowrap\">",
"     AST/upper",
"    </span>",
"    limit of normal (ULN) for AST, and the platelet count is expressed as",
"    <span class=\"nowrap\">",
"     platelets/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    &divide; 1000.",
"   </p>",
"   <p>",
"    As an example, a patient with an AST level of 90 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    in a lab with an ULN = 45 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    and a platelet count of",
"    <span class=\"nowrap\">",
"     120,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    would have an APRI of:",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     (2/120)",
"    </span>",
"    x 100 = 1.67.",
"   </p>",
"   <p>",
"    This predictive model consists of objective and readily available laboratory variables [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/52\">",
"     52",
"    </a>",
"    ]. Several studies have described test characteristics of the APRI mainly patients with HCV or",
"    <span class=\"nowrap\">",
"     HCV/HIV",
"    </span>",
"    coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/52-58\">",
"     52-58",
"    </a>",
"    ] and in patients with alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/59\">",
"     59",
"    </a>",
"    ]. Variable test characteristics have been reported (sensitivity 37 to 80 percent, specificity 30 to 100 percent, positive predictive values 57 to 100 percent, and negative predictive values of 45 to 98 percent) depending in part upon the cutoff value chosen and whether the test was being used to predict severe fibrosis or cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/60\">",
"     60",
"    </a>",
"    ]. A meta-analysis of 40 studies provided the following estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An APRI threshold of 0.7 had an estimated sensitivity and specificity of 77 and 72 percent for significant fibrosis.",
"     </li>",
"     <li>",
"      An APRI threshold of 1.0 had an estimated sensitivity and specificity of 76 and 72 percent for cirrhosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accuracy was lower in patients coinfected with HIV and HCV. Thus, the APRI appears most useful for excluding significant fibrosis in patients with chronic HCV.",
"   </p>",
"   <p>",
"    More sophisticated indices of fibrosis using these and other indirect markers have been developed to enhance accuracy for detecting and staging hepatic fibrosis in chronic liver disease. Examples include the PGA Index, FibroSure (FibroTest) assay and Actitest. Combination of the APRI with the FibroTest-FibroSure tests (a strategy referred to as \"SAFE\" biopsy (sequential algorithm for fibrosis evaluation)) had good overall accuracy for significant fibrosis and reduced the need for liver biopsy in patients with chronic hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     PGA index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PGA Index was devised originally as a simple biological index for detection of alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/63\">",
"     63",
"    </a>",
"    ]. It combines the measurement of the Prothrombin index, gamma glutamyl transferase level and apolipoprotein A1 (PGA). It has been validated in patients with a variety of chronic liver diseases but particularly alcoholic liver disease its accuracy for the detection of cirrhosis has ranged between 66 and 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     FibroIndex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FibroIndex (derived from the platelet count, AST, and gamma globulin measurements) has been proposed as a marker of significant fibrosis in chronic HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/65\">",
"     65",
"    </a>",
"    ]. Its accuracy is still being determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     FIB-4 index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FIB-4 combines biochemical values (platelet count, ALT and AST) and age. It had good predictive accuracy for advanced fibrosis in at least two studies involving patients with chronic HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In another report, it performed better than other serologic markers for predicting advanced fibrosis in patients with nonalcoholic fatty liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fibrometer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fibrometer test involves a combination of the platelet count, prothrombin index, AST, alfa 2 macroglobulin, hyaluronate, blood urea nitrogen, and age. It performed well in predicting severe fibrosis in patients with chronic viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/48,69,70\">",
"     48,69,70",
"    </a>",
"    ], but was no better than the FibroTest (below) in predicting severe fibrosis in alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     FibroTest and FibroSure",
"    </span>",
"    &nbsp;&mdash;&nbsp;FibroTest and FibroSure are identical tests marketed under different names in Europe and America. The test involves assessment of alpha 2 macroglobulin, alpha 2 globulin (haptoglobin), gamma globulin, apolipoprotein A1, gamma glutamyl transferase and total bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/72\">",
"     72",
"    </a>",
"    ]. Results from each test are combined to determine mild fibrosis (Metavir F 0 to 1), significant fibrosis (Metavir F2 to 4) or indeterminate stage. Sensitivity and specificity for detection of significant fibrosis (F2 or greater) are approximately 75 and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. The severity of disease was correctly identified as being mild or significant in approximately 46 percent of patients overall.",
"   </p>",
"   <p>",
"    FibroTest has also been evaluated in combination with FibroScan. In a study of 183 patients with chronic hepatitis C, the combination of these tests demonstrated an ROC area of 0.88 for F &gt;2, 0.95 for F &gt;3 and 0.95 for F &gt;4. When the FibroScan and FibroTest results agreed, liver biopsy examination confirmed them in 84 percent of cases for F &gt;2, in 95 percent for F &gt;3 and in 94 percent for F = 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, it is likely that a combination of serum biomarkers and FibroScan will complement each other and enhance accuracy of fibrosis detection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hepascore",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepascore involves a combination of bilirubin, GGT, hyaluronic acid, alfa 2 macroglobulin, age and gender. Hepascore was no more accurate than the FibroTest in patients with alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/71\">",
"     71",
"    </a>",
"    ]. In other studies, the Hepascore was useful for predicting fibrosis in hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ActiTest",
"    </span>",
"    &nbsp;&mdash;&nbsp;ActiTest is a modification of the FibroTest that incorporates ALT and reflects both liver fibrosis and necroinflammatory activity. ActiTest appears to improve identification of more advanced fibrosis associated with histological inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients with chronic HCV who have achieved a sustained virologic response to therapy show corresponding improvement in both ActiTest and FibroTest scores, supporting a role in monitoring response to treatment. A meta-analysis that included a total of 1570 patients concluded that these tests were a reliable alternative to liver biopsy in patients with chronic hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Proteomics and glycomics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patterns of proteins or glycoprotein can be assessed by mass spectroscopy of serum samples [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/81\">",
"     81",
"    </a>",
"    ]. These methods represent 'surrogate' markers of fibrosis, and in fact the identities of the peaks are generally not known. Nevertheless, impressive correlations have been reported, in particular a study from Belgium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/82\">",
"     82",
"    </a>",
"    ] combining serum glycomics with one of the noninvasive serum assays, the (FibroTest).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIRECT MARKERS OF FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver fibrosis results in both qualitative and quantitative changes in ECM markers. Potential markers of fibrosis include products of collagen synthesis or degradation, enzymes involved in matrix biosynthesis or degradation, extracellular matrix glycoproteins and",
"    <span class=\"nowrap\">",
"     proteoglycans/glycosaminoglycans.",
"    </span>",
"    Direct markers of fibrosis can be divided into:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Markers associated with matrix deposition",
"     </li>",
"     <li>",
"      Markers associated with matrix degradation",
"     </li>",
"     <li>",
"      Cytokines and chemokines associated with fibrogenesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Markers associated with matrix deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several markers associated with matrix deposition have been studied (",
"    <a class=\"graphic graphic_table graphicRef74005 \" href=\"UTD.htm?11/14/11499\">",
"     table 1",
"    </a>",
"    ). Most are based upon the detection of various procollagen peptides.",
"   </p>",
"   <p>",
"    Collagen is synthesized in a precursor form known as procollagen. Enzymatic cleavage at both the carboxyl- and amino-terminal ends of the procollagen molecule by two distinct enzymes, procollagen C-proteinase and procollagen N-proteinase, results in the formation of collagen molecules. Carboxy and amino-terminal procollagen peptides are cleaved off the procollagen molecule extracellularly during the synthesis of collagen fibrils and are released into the serum where they can be measured. Tests are available for the detection of procollagen type I carboxy-terminal peptide and procollagen type III amino-terminal peptide (PIIINP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Procollagen type I carboxy-terminal peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procollagen type I carboxy-terminal peptide (PICP) levels are increased in patients with cirrhosis. However, PICP are not as accurate as type IV collagen or the PIIINP in detecting the presence of cirrhosis, quantifying disease severity, or indicating the presence of associated alcoholic hepatitis.",
"   </p>",
"   <p>",
"    PICP levels have also been studied in patients with chronic hepatitis C. In one report, PICP levels were normal in those with mild chronic hepatitis and increased approximately 50 percent in those with moderate to severe hepatitis and those with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/83\">",
"     83",
"    </a>",
"    ]. In contrast to PIIINP, there was no correlation between levels of PICP and a sustained response to interferon-alpha therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Procollagen type III amino-terminal peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procollagen type III amino-terminal peptide (PIIINP or P3NP) levels are elevated in acute and chronic liver diseases and correlate with serum aminotransferase levels in patients with active hepatitis and with serum bilirubin levels in those with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/84\">",
"     84",
"    </a>",
"    ]. Serum levels of PIIINP reflect the histological stage of hepatic fibrosis in alcoholic liver disease, viral hepatitis, and primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. Reduction or normalization of PIIINP levels have been observed in those who abstain from alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/87,88\">",
"     87,88",
"    </a>",
"    ] and in those with autoimmune hepatitis who successfully responded to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/89\">",
"     89",
"    </a>",
"    ]. Hepatic venous blood has higher levels of PIIINP than peripheral venous or arterial samples. However, no association has been demonstrated between the levels of PIIINP and the degree of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis C &ndash; In patients with chronic hepatitis C, the serum levels of PIIINP correlate well with the histological scores for portal, periportal, and lobular necrosis, but only poorly for fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/93,94\">",
"       93,94",
"      </a>",
"      ]. However, the degree of correlation is insufficient for a single measurement to provide a reliable estimate of the stage of liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduction or normalization of PIIINP levels has been observed in patients who had a partial or a sustained virological and histological response to interferon monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/83,95,96\">",
"     83,95,96",
"    </a>",
"    ]. In addition, high pretreatment levels of PIIINP have been associated with a poor response to interferon monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcoholic liver disease &ndash; The correlation between PIIINP levels and fibrotic stage is relatively strong in patients with alcoholic liver disease. One study demonstrated a stepwise increase in PIIINP levels from chronic persistent hepatitis (8.7 &plusmn; 0.5",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      to chronic active hepatitis (20.8 &plusmn; 2.9",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      to alcoholic cirrhosis (47.7 &plusmn; 6.1",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/98\">",
"       98",
"      </a>",
"      ]. Levels were increased further in patients with acute alcoholic hepatitis superimposed upon underlying cirrhosis supporting the role of ethanol metabolites in fibrogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/85\">",
"       85",
"      </a>",
"      ]. As mentioned above, levels appear to decrease in patients who abstain from alcohol [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/87,88\">",
"       87,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis &ndash; PIIINP has been investigated extensively in primary biliary cirrhosis (PBC). In most reports, levels correlated with serum levels of bilirubin, alkaline phosphatase, aspartate aminotransferase, and albumin [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/99-102\">",
"       99-102",
"      </a>",
"      ], although discordant data have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/103\">",
"       103",
"      </a>",
"      ]. In addition, most studies found a correlation between serum levels of PIIINP and the histological stage of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/99,102,104\">",
"       99,102,104",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, care must be taken in interpreting these results as levels may reflect bone turn over in advanced PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/105\">",
"     105",
"    </a>",
"    ]. Furthermore, at least one study supported the use of PIIINP as a prognostic marker for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/85\">",
"     85",
"    </a>",
"    ] while other studies demonstrated a correlation with the Mayo risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/102,105\">",
"     102,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ursodeoxycholic acid (UDCA) has no impact on the serum levels of PIIINP, which is not surprising considering that UDCA does not appear to have any effect on established fibrous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/106\">",
"     106",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    and steroids reduced serum levels, although the mechanism by which this happens is unclear, and both drugs are ineffective for the treatment of PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Type I and IV collagens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of type I collagen are increased in all types of liver fibrosis. Messenger RNA levels of type I collagen are increased 60- to 70-fold in activated hepatic stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/107\">",
"     107",
"    </a>",
"    ]. Serum levels of type I collagen are increased in patients with chronic liver disease and correlate with fibrosis score but not with the inflammatory activity score [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/86\">",
"     86",
"    </a>",
"    ]. Despite this correlation, there is no association with portal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type IV collagen protein is located in the basement membrane of blood and lymph vessels, of bile ducts, around nerve axons, and in the perisinusoidal spaces. Immunofluorescence staining has demonstrated increased type IV collagen in the periportal interstitium and the large fibrotic areas in alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/108\">",
"     108",
"    </a>",
"    ]. Several assays are available for measuring different regions of the type IV collagen molecule: an amino-terminal domain (7S collagen), a central helix domain, and a carboxy-terminal domain. There is good correlation among the assays for each domain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum type IV collagen levels are increased in patients with chronic liver diseases compared with normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/110\">",
"     110",
"    </a>",
"    ]. One hypothesis suggests that the increased levels may reflect capillarization of the perisinusoidal wall seen in hepatic fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/108,111\">",
"     108,111",
"    </a>",
"    ]. Type IV collagen was more sensitive than laminin, hyaluronic acid, and PIIINP in diagnosing fibrosis in patients with chronic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/112\">",
"     112",
"    </a>",
"    ]. In a study of chronic HCV liver disease, type IV collagen was more useful than platelet count in differentiating moderate or severe fibrosis from no or mild fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcoholic liver disease &ndash; There is a significant correlation between type IV collagen levels and fibrotic stage and particularly perisinusoidal fibrosis in alcoholic liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/114\">",
"       114",
"      </a>",
"      ]. In addition, at least one study suggested that type IV collagen may be more sensitive and specific than Maddrey's criteria in identifying patients with severe alcoholic hepatitis and could thus possibly provide a useful noninvasive method for identifying critically ill patients that may benefit from glucocorticoid or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemochromatosis &ndash; Serum type IV collagen levels greater than 115",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      were 100 sensitive and 69 specific for the diagnosis of stage 3 to 4 fibrosis in hereditary hemochromatosis in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatitis C &ndash; In patients with chronic HCV infection, pretreatment levels of type IV collagen were lower in patients who had a sustained biochemical response to interferon monotherapy compared to those who had a transient response, consistent with the observation that fibrotic stage is predictive of response to interferon monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/97\">",
"       97",
"      </a>",
"      ]. In addition, reduction in type IV collagen levels occurred in association with improved histology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Laminin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laminin is non-collagenous glycoprotein synthesized by the hepatic stellate cells and deposited in the basement membrane of the liver. In chronic liver injury, basement membrane components, particularly laminin, are increasingly deposited around the vessels, in the perisinusoidal spaces, and in the portal tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/108,116\">",
"     108,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum levels of laminin and the pepsin-resistant fragment of laminin (laminin P1) are elevated in patients with chronic liver disease associated with alcohol and viral hepatitis, which may reflect an increase in perisinusoidal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/117\">",
"     117",
"    </a>",
"    ]. Serum levels of laminin correlate with the severity of fibrosis and hepatitis, Child's Pugh score, hepatic vein portal gradient, and complications of liver cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/118-121\">",
"     118-121",
"    </a>",
"    ]. It is a sensitive and specific marker of acute alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/53\">",
"     53",
"    </a>",
"    ]. Alcohol abstinence has been associated with a reduction in laminin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/87,122\">",
"     87,122",
"    </a>",
"    ]. In contrast, in patients with chronic HCV, treatment response is not always associated with normalization of serum laminin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/83,95,123\">",
"     83,95,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laminin appears to be superior to PIIINP but not as good as collagen type IV in predicting fibrotic stage in chronic viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/124\">",
"     124",
"    </a>",
"    ]. Analysis of hepatic venous blood levels of laminin is superior to peripheral blood or blood distal to the liver indicating either increased production or impaired degradation of laminin due to hepatic insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/91,122,125,126\">",
"     91,122,125,126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hyaluronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyaluronic acid (HA), a glycosaminoglycan synthesized by hepatic stellate cells and degraded by the liver sinusoidal cells, is a component of the extracellular matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/127\">",
"     127",
"    </a>",
"    ]. High levels of HA in patients with liver disease and particularly those with cirrhosis have been related to impaired function of the endothelial sinusoidal cells, and reflect increased fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcoholic liver disease &ndash; In alcoholic liver disease, serum levels of HA reflect the severity of hepatic inflammation and the amount of fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/129\">",
"       129",
"      </a>",
"      ]. There is a direct linear relationship between HA and PIIINP with similarities of both tests in discriminating between alcoholic patients with and without fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/129\">",
"       129",
"      </a>",
"      ]. Abstinence from alcohol is associated with reductions in HA levels.",
"     </li>",
"     <li>",
"      Hepatitis B and C &ndash; HA levels correlate with hepatic fibrosis but not with histopathological indices of necroinflammation in patients with chronic hepatitis B and C [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/130,131\">",
"       130,131",
"      </a>",
"      ]. The level of HA appears to be the most useful marker of hepatic fibrosis and an independent predictor of severe complications of cirrhosis in patients with hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/113,132\">",
"       113,132",
"      </a>",
"      ]. A reduction of HA levels has been observed in patients with HCV who had a biochemical response to interferon monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/131\">",
"       131",
"      </a>",
"      ]. Reduced levels of HA correlated with improvement in fibrosis, while increased levels were associated with worsening of fibrosis. Serum HA levels have the greatest predictive accuracy for advanced fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/133\">",
"       133",
"      </a>",
"      ]. Combined measurement of HA and other fibrosis markers has also been proposed for determining fibrosis in hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonalcoholic fatty liver disease &ndash; A predictive model that included serum levels of HA was useful in predicting liver fibrosis patients with features of the metabolic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/135\">",
"       135",
"      </a>",
"      ]. Further validation may help define its role in clinical practice. HA performed better than YKL-40 and TIMP-1 in predicting",
"      <span class=\"nowrap\">",
"       F3/F4",
"      </span>",
"      fibrosis with an AUROC of 0.77 versus 0.64 and 0.60 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis &ndash; HA performs better than PIIINP and type IV collagen in identifying patients with cirrhosis due to PBC or HCV [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/101,104,128,137\">",
"       101,104,128,137",
"      </a>",
"      ]. Furthermore, HA shows a negative correlation with survival in PBC patients and correlates well with portal vein pressure in a subgroup of patients with fibrotic liver diseases of various etiologies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/101,138\">",
"       101,138",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum hyaluronic acid has been assessed in combination with other laboratory tests as a predictor of hepatic fibrosis in the Hepascore, FibroSpect II, and SHASTA index. The FibroSpect II assay uses a combination of serum hyaluronic acid, tissue inhibitor of metalloproteinase 1 (TIMP-1), and alfa 2-macroglobulin. The combination of these assays reliably differentiates chronic hepatitis C with",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    fibrosis from",
"    <span class=\"nowrap\">",
"     no/mild",
"    </span>",
"    fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/133,139,140\">",
"     133,139,140",
"    </a>",
"    ]. Similarly, the combination of Serum Hyaluronic Acid level with serum AST and Albumin level (SHASTA) has been evaluated in patients with HIV and HCV co-infection and using a cutoff value of 0.8 for the AUROC gives a specificity of 100 percent and a positive predictive value of 100 percent. At the other end of the spectrum a cutoff of &lt;0.30 was associated with a sensitivity of &gt;88 percent and a negative predictive value of &gt;94 percent. Overall 42 percent of patients could be correctly classified at either extreme however 58 percent would not be classifiable with scores between 0.3 and 0.8 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Chondrex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrex (YKL-40) is a 38-kDA glycoprotein, a member of the chitinase family initially described in patients with arthritis, that is strongly correlated with the activity of arthritis. The function of YKL-40 is unknown but the pattern of its expression in certain tissues, such as human liver or cartilage, suggests a function in remodeling or degradation of extracellular matrix.",
"   </p>",
"   <p>",
"    Immunohistochemical staining of fibrotic liver tissue has demonstrated YKL-40 in areas of fibrosis and in particular areas with active fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/141\">",
"     141",
"    </a>",
"    ]. Serum levels of YKL-40 are increased in patients with alcoholic liver disease, particularly those with alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. The serum levels are significantly correlated with the degree of liver fibrosis and the plasma level of hyaluronic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/143\">",
"     143",
"    </a>",
"    ]. Elevated serum levels have also been described in patients with post-necrotic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/141\">",
"     141",
"    </a>",
"    ]. Levels of YKL-40 in the hepatic vein are significantly higher that the femoral artery, indicating that YKL-40 is derived from the splanchnic circulation in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/142\">",
"     142",
"    </a>",
"    ]. Elevation of YKL-40 correlates with the degree of hepatic fibrosis. A study comparing it to the FibroSpect II assay and serum hyaluronic acid levels found that YKL-40 had the highest false-positive rate for predicting fibrosis in patients with chronic hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MARKERS ASSOCIATED WITH MATRIX DEGRADATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matrix degradation occurs predominantly as a consequence of the action of a family of enzymes known as the matrix metalloproteinases (MMPs). These enzymes are synthesized intracellularly and are secreted in a pro-enzyme form requiring cleavage by cell surface mechanisms for functional activity. They are in turn inhibited by tissue inhibitors of metalloproteinases (TIMPs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link\">",
"     \"Pathogenesis of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The observation that MMPs are expressed in liver injury suggests that degradation of normal liver matrix may contribute to the pathogenesis of hepatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/123\">",
"     123",
"    </a>",
"    ]. The three most important MMPs appear to be: MMP-2 (gelatinase-A), MMP-3 (stromelysin) and MMP-9 (gelatinase-B).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Matrix metalloproteinase-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMP-2 is secreted by activated hepatic stellate cells. It is significantly increased by the presence of collagen type-I. In human liver diseases and animal models of liver disease, there is increased expression of the MMP-2 proenzyme and active enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/144,145\">",
"     144,145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the production of MMP-2 in chronic liver disease, several studies investigating the correlation of serum levels of MMP-2 with the degree of hepatic fibrosis in chronic hepatitis C infection have yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/113,146,147\">",
"     113,146,147",
"    </a>",
"    ]. These differences may be explained by the use of different assay systems in the studies, which highlights the need for standardization of assays if they are to be useful in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Matrix metalloproteinase-3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very little is known about the expression of MMP-3 in liver injury and fibrosis. However, one study reports that serum levels of MMP-3 are not useful for predicting hepatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Matrix metalloproteinase-9",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMP-9 is predominantly secreted by activated Kupffer cells and possibly activated from the proenzyme formed by the hepatic stellate cell [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/149\">",
"     149",
"    </a>",
"    ]. Plasma levels of MMP-9 are increased in patients with hepatocellular carcinoma but not those with chronic hepatitis or cirrhosis when compared with normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     TIMP-1 and 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothesis that progression of chronic fibrotic liver disease is associated with inhibition of matrix degradation is strongly suggested from cultures of hepatic stellate cells. MMP-13 is transiently increased after a few days of culture, but rapidly becomes undetectable. In contrast, TIMP-1 and TIMP-2 levels increase dramatically and remain elevated for the duration of the culture. This is consistent with the data from human explant liver tissue demonstrating increased expression of TIMP-1 and &ndash;2 in patients with sclerosing cholangitis, biliary atresia, PBC, and autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/151,152\">",
"     151,152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In chronic HCV disease, serum TIMP-1 and TIMP-2 levels were significantly correlated with the histological activity index and with fibrosis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/147\">",
"     147",
"    </a>",
"    ]. TIMP-1 levels had a sensitivity of 100 percent in diagnosing cirrhosis but had a low specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/153\">",
"     153",
"    </a>",
"    ]. In another report, TIMP-1 levels correlated with type IV collagen, PIIINP, and laminin P1 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     CYTOKINE AND CHEMOKINES ASSOCIATED WITH HEPATIC FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of cytokines having a role in hepatic fibrogenesis have been identified, some of which may be useful clinical markers of hepatic fibrogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link\">",
"     \"Pathogenesis of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Transforming growth factor beta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transforming growth factor beta (TGF beta) is the dominant stimulus for the production of extracellular matrix by hepatic stellate cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link\">",
"     \"Pathogenesis of hepatic fibrosis\"",
"    </a>",
"    .) Hepatic mRNA levels of TGF beta are increased in chronic liver disease in association with increases in mRNA levels of type 1 collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/155\">",
"     155",
"    </a>",
"    ]. Levels of TGF beta decrease in response to a reduction in the necroinflammatory activity with interferon therapy of chronic HCV in the absence of changes in fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/156,157\">",
"     156,157",
"    </a>",
"    ]. Furthermore, serum levels of total and biologically active TGF beta are increased in HCV related chronic liver disease compared with controls and correlate with fibrosis score [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Transforming growth factor alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transforming growth factor alpha (TGF alpha) is a potent stimulant of mitosis of normal and neoplastic hepatocytes. In addition, TGF alpha also appears to have a pivotal role in hepatocarcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/159\">",
"     159",
"    </a>",
"    ]. TGF-alpha levels are increased in patients with cirrhosis and correlate with bilirubin and Child's Pugh classification, suggesting they are closely correlated with the severity of liver dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Platelet derived growth factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet derived growth factor (PDGF) is upregulated following liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/161\">",
"     161",
"    </a>",
"    ]. At least one study suggested that the amount of PDGF levels correlated with the severity of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/59/30650/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a need for noninvasive diagnostics of liver fibrosis. Assessment of fibrosis progression in chronic HCV infection, for example, can be valuable in HCV for at least four reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stage of fibrosis helps predict the likelihood of response to interferon-based therapy, since advanced stages of fibrosis (Metavir F3 or F4) generally have a lower response.",
"     </li>",
"     <li>",
"      Treatment may be delayed or deferred if little fibrosis progression has occurred over a long interval.",
"     </li>",
"     <li>",
"      The approximate time to the development of cirrhosis can be estimated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While tremendous progress has been made in improving the accuracy of serum markers of hepatic fibrosis, they cannot yet supplant direct analysis of the liver. The ideal fibrosis marker is one that is specific, biologically based, noninvasive, easily repeated in all patients, correlates well with disease severity and outcome, and is not confounded by co-morbidities or drugs. Although this ideal has nearly been reached, no serum test has emerged as the perfect marker of fibrosis; all the serum tests have limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They typically reflect the rate of matrix turnover, not deposition, and thus tend to be more elevated when there is high inflammatory activity. In contrast, extensive matrix deposition can go undetected if there is minimal inflammation.",
"     </li>",
"     <li>",
"      None of the molecules are liver-specific, so that concurrent sites of inflammation may contribute to serum levels.",
"     </li>",
"     <li>",
"      Serum levels are affected by clearance rates, which may be impaired either due to sinusoidal endothelial cell dysfunction or impaired biliary excretion.",
"     </li>",
"     <li>",
"      They are surrogates, not biomarkers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are currently four commercial serum marker systems that have been most extensively validated: the FibroSpect (Prometheus Corp), the FibroTest (marketed in the United States by Labcorp), Hepascore (Quest Diagnostics), and the European Liver Fibrosis Study Group panel (not available in the United States), which uses a diagnostic algorithm and assays developed by Siemens Healthcare Diagnostics. In addition, a growing list of other noninvasive tests have been developed using a variety of standard serum hematologic or chemistry in varying combinations.",
"   </p>",
"   <p>",
"    There are few discernible differences among the three major serum assays, and their value can be summarized as the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tests are extremely accurate (&gt;95 percent) in determining the near absence (F0 or F1) of fibrosis in HCV or presence of cirrhosis, but not for intermediate stages. Thus in select clinical circumstances the findings from these tests may obviate the need for biopsy or help guide decisions about treatment with antiviral combinations. Less is known about their value in patients with liver diseases other than HCV, but data are beginning to emerge.",
"     </li>",
"     <li>",
"      They suffer from a variable but significant number of indeterminate outcomes (up to 50 percent with the FibroTest).",
"     </li>",
"     <li>",
"      There is no evidence that any test can discern changes in fibrosis content over time in an individual patient, although these tests are proving valuable in cohort studies, where mean changes in serum values among a group of patients will correlate with changes in fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the serum assay approaches remain promising, in part because these tests may represent an integrated readout of liver activity, rather than a minute sampling of the type obtained by conventional liver biopsy. Continued refinements are likely, and they already have established an important niche, especially in patients who have a high risk of complications from liver biopsy, or patients with liver disease not under the care of a",
"    <span class=\"nowrap\">",
"     hepatologist/gastroenterologist",
"    </span>",
"    (eg, patients coinfected with",
"    <span class=\"nowrap\">",
"     HCV/HIV).",
"    </span>",
"   </p>",
"   <p>",
"    Cross sectional imaging studies such as CT, MRI, and US ultrasound are only capable of supporting a clinical or histological diagnosis of cirrhosis. However, a novel ultrasound technique that measures hepatic elasticity can reliably identify advanced fibrosis. Its clinical role is still being determined. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Liver stiffness'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/1\">",
"      Harbin WP, Robert NJ, Ferrucci JT Jr. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology 1980; 135:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/2\">",
"      Aub&eacute; C, Oberti F, Korali N, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/3\">",
"      Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/4\">",
"      Liu CH, Hsu SJ, Lin JW, et al. Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Clin Gastroenterol Hepatol 2007; 5:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/5\">",
"      Lewin M, Poujol-Robert A, Bo&euml;lle PY, et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/6\">",
"      Sandrin L, Tanter M, Gennisson JL, et al. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002; 49:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/7\">",
"      Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/8\">",
"      Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007; 46:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/9\">",
"      Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/10\">",
"      Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/11\">",
"      Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/12\">",
"      Adebajo CO, Talwalkar JA, Poterucha JJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012; 18:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/13\">",
"      Merchante N, Rivero-Ju&aacute;rez A, T&eacute;llez F, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012; 56:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/14\">",
"      Cescon M, Colecchia A, Cucchetti A, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012; 256:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/15\">",
"      Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010; 52:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/16\">",
"      Cast&eacute;ra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/17\">",
"      Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 2012; 56:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/18\">",
"      de L&eacute;dinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan&reg;. J Hepatol 2012; 56:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/19\">",
"      Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/20\">",
"      Roulot D, Czernichow S, Le Cl&eacute;siau H, et al. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/21\">",
"      Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/22\">",
"      Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/23\">",
"      Mueller S, Millonig G, Sarovska L, et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010; 16:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/24\">",
"      Tapper EB, Cohen EB, Patel K, et al. Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2012; 10:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/25\">",
"      Janssens F, de Suray N, Piessevaux H, et al. Can transient elastography replace liver histology for determination of advanced fibrosis in alcoholic patients: a real-life study. J Clin Gastroenterol 2010; 44:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/26\">",
"      Wong GL, Wong VW, Choi PC, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008; 6:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/27\">",
"      Ochi H, Hirooka M, Koizumi Y, et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012; 56:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/28\">",
"      Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology 2012; 56:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/29\">",
"      Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/30\">",
"      Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/31\">",
"      Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/32\">",
"      Palmeri ML, Wang MH, Rouze NC, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/33\">",
"      Boursier J, Isselin G, Fouchard-Hubert I, et al. Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. Eur J Gastroenterol Hepatol 2010; 22:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/34\">",
"      Haque M, Robinson C, Owen D, et al. Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. Ann Hepatol 2010; 9:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/35\">",
"      Kim JE, Lee JY, Kim YJ, et al. Acoustic radiation force impulse elastography for chronic liver disease: comparison with ultrasound-based scores of experienced radiologists, Child-Pugh scores and liver function tests. Ultrasound Med Biol 2010; 36:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/36\">",
"      Kuroda H, Kakisaka K, Tatemichi Y, et al. Non-invasive evaluation of liver fibrosis using acoustic radiation force impulse imaging in chronic hepatitis patients with hepatitis C virus infection. Hepatogastroenterology 2010; 57:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/37\">",
"      Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2011; 106:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/38\">",
"      Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis 2009; 18:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/39\">",
"      Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int 2010; 30:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/40\">",
"      Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/41\">",
"      Fierbinteanu-Braticevici C, Andronescu D, Usvat R, et al. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. World J Gastroenterol 2009; 15:5525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/42\">",
"      Crespo G, Fern&aacute;ndez-Varo G, Mari&ntilde;o Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012; 57:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/43\">",
"      Yoon KT, Lim SM, Park JY, et al. Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci 2012; 57:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/44\">",
"      Ferraioli G, Tinelli C, Dal Bello B, et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012; 56:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/45\">",
"      Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/46\">",
"      Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006; 44:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/47\">",
"      Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/48\">",
"      Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/49\">",
"      Cal&egrave;s P, Halfon P, Batisse D, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol 2010; 53:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/50\">",
"      Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/51\">",
"      Cal&egrave;s P, de Ledinghen V, Halfon P, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/52\">",
"      Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/53\">",
"      Cast&eacute;ra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/54\">",
"      Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/55\">",
"      Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005; 40:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/56\">",
"      Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/57\">",
"      Schiavon LL, Schiavon JL, Filho RJ, et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 46:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/58\">",
"      Singal AG, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther 2011; 33:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/59\">",
"      Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006; 101:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/60\">",
"      Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/61\">",
"      Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/62\">",
"      Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/63\">",
"      Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/64\">",
"      Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/65\">",
"      Koda M, Matunaga Y, Kawakami M, et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/66\">",
"      Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/67\">",
"      Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/68\">",
"      Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/69\">",
"      Cal&egrave;s P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/70\">",
"      Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/71\">",
"      Naveau S, Gaud&eacute; G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/72\">",
"      Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/73\">",
"      Myers RP, De Torres M, Imbert-Bismut F, et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003; 48:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/74\">",
"      Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/75\">",
"      Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003; 49:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/76\">",
"      Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/77\">",
"      Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/78\">",
"      Becker L, Salameh W, Sferruzza A, et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009; 7:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/79\">",
"      Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/80\">",
"      Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/81\">",
"      Petricoin E, Wulfkuhle J, Espina V, Liotta LA. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res 2004; 3:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/82\">",
"      Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/83\">",
"      Gallorini A, Plebani M, Pontisso P, et al. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon. Liver 1994; 14:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/84\">",
"      Montalto G, Soresi M, Aragona F, et al. [Procollagen III and laminin in chronic viral hepatopathies]. Presse Med 1996; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/85\">",
"      Teare JP, Sherman D, Greenfield SM, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/86\">",
"      Trinchet JC, Hartmann DJ, Pateron D, et al. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J Hepatol 1991; 12:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/87\">",
"      Niemel&auml; O, Risteli J, Blake JE, et al. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990; 98:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/88\">",
"      Nouchi T, Worner TM, Sato S, Lieber CS. Serum procollagen type III N-terminal peptides and laminin P1 peptide in alcoholic liver disease. Alcohol Clin Exp Res 1987; 11:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/89\">",
"      McCullough AJ, Stassen WN, Wiesner RH, Czaja AJ. Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis. J Lab Clin Med 1987; 109:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/90\">",
"      Gressner AM, Tittor W. Serum laminin--its concentration increases with portal hypertension in cirrhotic liver disease. Klin Wochenschr 1986; 64:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/91\">",
"      Gressner AM, Tittor W, Kropf J. Evaluation of serum aminoterminal procollagen type III propeptide as an index of portal hypertension and esophageal varices in chronic liver diseases. Clin Chim Acta 1988; 174:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/92\">",
"      Mal F, Hartmann DJ, Trinchet JC, et al. [Serum laminin and portal pressure in alcoholic cirrhosis. A study of 39 patients]. Gastroenterol Clin Biol 1988; 12:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/93\">",
"      Gabrielli GB, Capra F, Casaril M, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997; 265:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/94\">",
"      Giannini E, Caglieris S, Ceppa P, et al. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2001; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/95\">",
"      Capra F, Casaril M, Gabrielli GB, et al. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993; 18:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/96\">",
"      Yagura M, Murai S, Kojima H, et al. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method. J Gastroenterol 2000; 35:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/97\">",
"      Yabu K, Kiyosawa K, Mori H, et al. Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 1994; 29:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/98\">",
"      Raedsch R, Stiehl A, Waldherr R, et al. Procollagen-type III-peptide serum concentrations in chronic persistent and chronic active hepatitis and in cirrhosis of the liver and their diagnostic value. Z Gastroenterol 1982; 20:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/99\">",
"      Mutimer DJ, Bassendine MF, Kelly P, James OF. Is measurement of type III procollagen amino propeptide useful in primary biliary cirrhosis? J Hepatol 1989; 9:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/100\">",
"      Remmel T, Remmel H, Salupere V. Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fibrosis in primary biliary cirrhosis. J Gastroenterol Hepatol 1996; 11:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/101\">",
"      Nyberg A, Lindqvist U, Engstr&ouml;m-Laurent A. Serum hyaluronan and aminoterminal propeptide of type III procollagen in primary biliary cirrhosis: relation to clinical symptoms, liver histopathology and outcome. J Intern Med 1992; 231:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/102\">",
"      Babbs C, Smith A, Hunt LP, et al. Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet 1988; 1:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/103\">",
"      Beukers R, van Zanten RA, Schalm SW. Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis. J Hepatol 1992; 14:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/104\">",
"      Plebani M, Giacomini A, Floreani A, et al. Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. Ric Clin Lab 1990; 20:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/105\">",
"      Pereira SP, Bray GP, Pitt PI, et al. Non-invasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/106\">",
"      Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/107\">",
"      Stefanovic B, Hellerbrand C, Holcik M, et al. Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells. Mol Cell Biol 1997; 17:5201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/108\">",
"      Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 1980; 21:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/109\">",
"      Murawaki Y, Ikuta Y, Koda M, et al. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol 1996; 24:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/110\">",
"      George DK, Ramm GA, Walker NI, et al. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis. J Hepatol 1999; 31:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/111\">",
"      Yokoya Y, Iwata K, Muragaki Y, et al. Concentration of serum laminin and type IV collagen in liver diseases assayed by a sandwich enzyme-immunoassay using monoclonal antibodies. Clin Chim Acta 1992; 210:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/112\">",
"      Xie J, OuYang K, Su T. [Serum type IV collagen and laminin in patients with chronic hepatitis and its clinical significance]. Hunan Yi Ke Da Xue Xue Bao 1998; 23:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/113\">",
"      Murawaki Y, Ikuta Y, Okamoto K, et al. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001; 36:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/114\">",
"      Ueno T, Inuzuka S, Torimura T, et al. Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. Scand J Gastroenterol 1992; 27:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/115\">",
"      Castera L, Hartmann DJ, Chapel F, et al. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 2000; 32:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/116\">",
"      Matsumoto S, Yamamoto K, Nagano T, et al. Immunohistochemical study on phenotypical changes of hepatocytes in liver disease with reference to extracellular matrix composition. Liver 1999; 19:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/117\">",
"      Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol 2000; 32:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/118\">",
"      Annoni G, Colombo M, Cantaluppi MC, et al. Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers. Hepatology 1989; 9:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/119\">",
"      Kondo M, Miszputen SJ, Leite-mor MM, Parise ER. The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels. Hepatogastroenterology 1995; 42:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/120\">",
"      K&ouml;rner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996; 25:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/121\">",
"      K&ouml;rner T, Kropf J, Gressner AM. [The clinical value of laminin determination in advanced liver cirrhosis]. Dtsch Med Wochenschr 1996; 121:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/122\">",
"      Collazos J, D&iacute;az F, Genoll&aacute; J. Serum concentrations of laminin in cirrhosis of the liver. Gut 1993; 34:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/123\">",
"      Fabris P, Marranconi F, Bozzola L, et al. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. J Gastroenterol 1999; 34:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/124\">",
"      Misaki M, Shima T, Yano Y, et al. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease. Clin Chem 1990; 36:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/125\">",
"      Gressner AM, Tittor W, Negwer A. Serum concentrations of N-terminal propeptide of type III procollagen and laminin in the outflow of fibrotic livers compared with liver-distal regions. Hepatogastroenterology 1986; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/126\">",
"      Gressner AM, Kropf J. Concentration of laminin in serum related to the degree of esophageal varices in fibrotic liver diseases. Clin Chem 1988; 34:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/127\">",
"      McGary CT, Raja RH, Weigel PH. Endocytosis of hyaluronic acid by rat liver endothelial cells. Evidence for receptor recycling. Biochem J 1989; 257:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/128\">",
"      Gu&eacute;chot J, Laudat A, Loria A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/129\">",
"      Par&eacute;s A, Deulofeu R, Gim&eacute;nez A, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/130\">",
"      Pontinha N, Pessegueiro H, Barros H. Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis B. Scand J Clin Lab Invest 1999; 59:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/131\">",
"      Gu&eacute;chot J, Loria A, Serfaty L, et al. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995; 22:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/132\">",
"      Gu&eacute;chot J, Serfaty L, Bonnand AM, et al. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000; 32:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/133\">",
"      Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008; 103:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/134\">",
"      Fontana RJ, Goodman ZD, Dienstag JL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/135\">",
"      Lain&eacute; F, Bendavid C, Moirand R, et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology 2004; 39:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/136\">",
"      Malik R, Chang M, Bhaskar K, et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/137\">",
"      Murawaki Y, Ikuta Y, Koda M, et al. Clinical significance of serum hyaluronan in patients with chronic viral liver disease. J Gastroenterol Hepatol 1996; 11:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/138\">",
"      Kropf J, Gressner AM, Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 1991; 37:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/139\">",
"      Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/140\">",
"      Patel K, Nelson DR, Rockey DC, et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/141\">",
"      Johansen JS, Christoffersen P, M&oslash;ller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/142\">",
"      Johansen JS, M&oslash;ller S, Price PA, et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997; 32:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/143\">",
"      Tran A, Benzaken S, Saint-Paul MC, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000; 12:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/144\">",
"      Takahara T, Furui K, Funaki J, et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995; 21:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/145\">",
"      Takahara T, Furui K, Yata Y, et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997; 26:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/146\">",
"      Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997; 26:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/147\">",
"      Walsh KM, Timms P, Campbell S, et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999; 44:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/148\">",
"      Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/149\">",
"      Ueno T, Sujaku K, Tamaki S, et al. OK-432 treatment increases matrix metalloproteinase-9 production and improves dimethylnitrosamine-induced liver cirrhosis in rats. Int J Mol Med 1999; 3:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/150\">",
"      Hayasaka A, Suzuki N, Fujimoto N, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996; 24:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/151\">",
"      Benyon RC, Iredale JP, Goddard S, et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/152\">",
"      Iredale JP, Goddard S, Murphy G, et al. Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. Clin Sci (Lond) 1995; 89:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/153\">",
"      Boeker KH, Haberkorn CI, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/154\">",
"      Ueno T, Tamaki S, Sugawara H, et al. Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases. J Hepatol 1996; 24:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/155\">",
"      Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-beta 1 gene expression in human liver disease. J Hepatol 1992; 14:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/156\">",
"      Bedossa P, Poynard T, Mathurin P, et al. Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. Gut 1993; 34:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/157\">",
"      Roulot D, Durand H, Coste T, et al. Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology 1995; 21:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/158\">",
"      Nelson DR, Gonzalez-Peralta RP, Qian K, et al. Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat 1997; 4:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/159\">",
"      Chung YH, Kim JA, Song BC, et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000; 89:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/160\">",
"      Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999; 19:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/161\">",
"      Ikura Y, Morimoto H, Ogami M, et al. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol 1997; 32:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/59/30650/abstract/162\">",
"      Shiraishi T, Morimoto S, Koh E, et al. Increased release of platelet-derived growth factor from platelets in chronic liver disease. Eur J Clin Chem Clin Biochem 1994; 32:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1239 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30650=[""].join("\n");
var outline_f29_59_30650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CROSS-SECTIONAL IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIVER STIFFNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69601958\">",
"      Ultrasound-based transient elastography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69601973\">",
"      Magnetic resonance elastography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69601980\">",
"      Other ultrasound-based techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SERUM BIO-MARKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INDIRECT MARKERS OF FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AST/ALT ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AST to platelet ratio index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PGA index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FibroIndex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FIB-4 index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fibrometer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FibroTest and FibroSure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hepascore",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ActiTest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Proteomics and glycomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIRECT MARKERS OF FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Markers associated with matrix deposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Procollagen type I carboxy-terminal peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Procollagen type III amino-terminal peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Type I and IV collagens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Laminin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hyaluronic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Chondrex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MARKERS ASSOCIATED WITH MATRIX DEGRADATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Matrix metalloproteinase-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Matrix metalloproteinase-3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Matrix metalloproteinase-9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TIMP-1 and 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      CYTOKINE AND CHEMOKINES ASSOCIATED WITH HEPATIC FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Transforming growth factor beta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Transforming growth factor alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Platelet derived growth factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/14/11499\" title=\"table 1\">",
"      Fibrosis markers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=related_link\">",
"      Pathogenesis of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_59_30651="Bleomycin lung injury symptoms";
var content_f29_59_30651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical presentation of bleomycin-induced lung injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dyspnea (75-90 percent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonproductive cough (50-93 percent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\" rowspan=\"2\">",
"            Chest discomfort",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tachypnea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rales",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Laboratory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Restrictive PFTs with a low diffusing capacity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Widened alveolar-arterial gradient",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\" rowspan=\"2\">",
"            No eosinophilia (except in hypersensitivity-like reaction)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30651=[""].join("\n");
var outline_f29_59_30651=null;
var title_f29_59_30652="Virology of the common cold";
var content_f29_59_30652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiologic and clinical features of viruses that cause the common cold in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Virus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proportion of cases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predominant months of circulation*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other clinical syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhinoviruses",
"        <br/>",
"        (more than 100 serotypes)",
"       </td>",
"       <td>",
"        30 to 50 percent",
"       </td>",
"       <td>",
"        Present year round with a peak in September and a smaller peak in March and April",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory syncytial virus",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"       <td>",
"        November to March",
"       </td>",
"       <td>",
"        Bronchiolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza viruses",
"       </td>",
"       <td>",
"        5 to 15 percent",
"       </td>",
"       <td>",
"        Winter months, with peak in February",
"       </td>",
"       <td>",
"        <p>",
"         Influenza",
"        </p>",
"        <p>",
"         Croup",
"        </p>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parainfluenza viruses",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"       <td>",
"        September to January with peak in October and November",
"       </td>",
"       <td>",
"        Croup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoviruses",
"       </td>",
"       <td>",
"        &lt;5 percent",
"       </td>",
"       <td>",
"        September to May",
"       </td>",
"       <td>",
"        Pharyngoconjunctival fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroviruses",
"        <br/>",
"        (echoviruses and coxsackieviruses)",
"       </td>",
"       <td>",
"        &lt;5 percent",
"       </td>",
"       <td>",
"        Present year round, with a peak during the summer",
"       </td>",
"       <td>",
"        <p>",
"         Aseptic meningitis (non-polio enteroviruses)",
"        </p>",
"        Herpangina (cocksackievirus type A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronaviruses",
"       </td>",
"       <td>",
"        10 to 15 percent",
"       </td>",
"       <td>",
"        November to February",
"       </td>",
"       <td>",
"        <p>",
"         Pneumonia",
"        </p>",
"        Croup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human metapneumovirus",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Late winter and early spring",
"       </td>",
"       <td>",
"        <p>",
"         Pneumonia",
"        </p>",
"        Bronchitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In the northern hemisphere.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Heikkinen T, J&auml;rvinen A. The common cold. Lancet 2003; 361:51.",
"      </li>",
"      <li>",
"       Kirkpatrick GL. The common cold. Prim Care 1996; 23:657.",
"      </li>",
"      <li>",
"       Pappas DE, Hendley JO. The common cold. In: Principles and Practice of Pediatric Infectious Diseases, 3rd, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, Philadelphia 2008. p.203.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30652=[""].join("\n");
var outline_f29_59_30652=null;
var title_f29_59_30653="Weight gain with glitazones";
var content_f29_59_30653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Weight gain with thiazolidinediones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Weight increased in both a time and dose dependent fashion in patients with type 2 diabetes who were treated with different thiazolidinediones for six months.",
"    <div class=\"footnotes\">",
"     T200, T400, and T600: troglitazone 200, 400, and 600 mg daily; P15 and P45: pioglitazone 15 and 45 mg daily; R4 and R8: rosiglitazone 4 and 8 mg daily.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <ol>",
"      <li>",
"       Arnoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23:1605.",
"      </li>",
"      <li>",
"       Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695.",
"      </li>",
"      <li>",
"       Schwartz S, Raskin P, Fonseca V, Graveline JF.&nbsp;Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338:861.",
"      </li>",
"      <li>",
"       Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes.&nbsp;Diabetes Care 2000; 23:1067.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30653=[""].join("\n");
var outline_f29_59_30653=null;
var title_f29_59_30654="Cesarean delivery rates in the US";
var content_f29_59_30654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    1989-2007 US total cesarean, primary cesarean, and VBAC rates",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 402px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data on total cesarean birth rate is comparable between the 2003 United States Standard Certificate of Live Birth (revised) and the 1989 version of the birth certificate (unrevised).",
"    <br/>",
"    Data on primary cesarean and vaginal birth after cesarean (VBAC) rates are not comparable between the 2003 United States Standard Certificate of Live Birth (revised) and the 1989 version of the birth certificate (unrevised).",
"    <div class=\"footnotes\">",
"     CS: cesarean delivery; VBAC: vaginal birth after cesarean.",
"    </div>",
"    <div class=\"reference\">",
"     Additional information:",
"     <br>",
"      <ol>",
"       <li>",
"        National Center for Health Statistics. User guide to the 2008 natality public use file. Hyattsville, MD: National Center for Health Statistics, 2010.",
"       </li>",
"       <li>",
"        National Center for Health Statistics. User guide to the 2009 natality public use file. Hyattsville, MD: National Center for Health Statistics, 2011.",
"       </li>",
"       <li>",
"        National Center for Health Statistics. User Guide to the 2010 Natality Public Use File. Hyattsville, MD: National Center for Health Statistics, 2012.",
"       </li>",
"      </ol>",
"      Reproduced from: Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews MS, Osterman MJ. Births: Final Data for 2008. Natl Vital Stat Rep 2010; 59:105.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30654=[""].join("\n");
var outline_f29_59_30654=null;
var title_f29_59_30655="Dissection of the abdominal aorta on transverse ultrasound";
var content_f29_59_30655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the abdominal aorta on transverse ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view shows a dissection (Dis) of the abdominal aorta (AoAb) and a spiral flap (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_59_30655=[""].join("\n");
var outline_f29_59_30655=null;
